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1 Abstract 
An expert review of the aetiology, assessment, and treatment of autism spectrum 
disorder (ASD), and recommendations for diagnosis, management and service 
provision was coordinated by the British Association for Psychopharmacology, and 
evidence graded.  
 
The aetiology of ASD involves genetic and environmental contributions, and implicates 
a number of brain systems, in particular the gamma-aminobutyric acid (GABA), 
serotonergic and glutamatergic systems. The presentation of ASD varies widely and 
co-occurring health problems (in particular epilepsy, sleep disorders, anxiety, 
depression, attention deficit/hyperactivity disorder (ADHD), and irritability) are 
common. We did not recommend the routine use of any pharmacological treatment for 
the core symptoms of ASD. In children, melatonin may be useful to treat sleep 
problems, dopamine blockers for irritability, and methylphenidate, atomoxetine and 
guanfacine for ADHD. The evidence for use of medication in adults is limited and 
recommendations are largely based on extrapolations from studies in children and 
patients without ASD. We discuss the conditions for considering and evaluating a trial 
of medication treatment, when non-pharmacological interventions should be 
considered, and make recommendations on service delivery. Finally, we identify key 
gaps and limitations in the current evidence base and make recommendations for 
future research and the design of clinical trials. 
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2 Introduction 
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with an estimated 
lifetime prevalence of at least 1% (Baird et al., 2006; Brugha et al., 2011). Core 
symptoms include deficits in social communication and the presence of restricted and 
repetitive interests or activities and sensory anomalies, beginning in the early 
developmental period (American Psychiatric Association, 2013). The assessment and 
management of ASD is complex, due to its multifactorial aetiology, persistence into 
adulthood, presence of co-occurring mental and physical disorders and attendant 
disability. The total cost, including accommodation, treatment, loss of earnings and 
health care for individuals over their life span has been estimated to range between 
£1.5 million to £0.92 million for someone with or without intellectual disability, 
respectively (Buescher et al., 2014). ASD-related difficulties are lifelong and often 
require on-going support. Many people with ASD are prescribed psychotropic 
medications at some point in their lives. According to a recent study in the UK using a 
representative primary care database, psychotropic drugs are prescribed to 29% of 
people with ASD (Murray et al., 2014). In this study, the most commonly prescribed 
categories of drugs for ASD were sleep medications (9.7%), psychostimulants (7.9%) 
and antipsychotics (7.3%) (Murray et al., 2014). In particular, the use of 
psychostimulants and antipsychotics in ASD is much higher than in the general 
population (Murray et al., 2014). Similar rates of prescribing psychotropic drugs have 
also been reported in the US and Canada. For example, a recent study of over 2,800 
children from the Autism Treatment Network in North America reported that 27% of 
children and adolescents with ASD are prescribed at least one psychotropic 
medication (Coury et al., 2012). Stimulants were most often prescribed (13%), followed 
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by selective serotonin re-uptake inhibitors (SSRIs) (8%) and atypical antipsychotics 
(8%) (Coury et al., 2012). Evidence also indicates that prescription rates have 
increased, with a more than three-fold increase in antidepressant drug prescriptions 
for people with ASD in the US between 1992 and 2001 (Aman et al., 2005b). Sixty per 
cent of adults with ASD have concerns about taking medications, particularly due to 
side-effects and lack of effectiveness (Wallace et al., 2013). This, and the 
commonplace use of drugs in ASD, suggests there is a need for comprehensive 
guidance on the assessment and management of ASD, which incorporates advice on 
the use of psychotropic medications. However, it should be recognised that some 
people with ASD do not want treatment for the core aspects of ASD. As such, 
discussion about treatment should take into consideration individual preferences. 
 
In view of the uncertainties, the British Association for Psychopharmacology 
coordinated the development of this consensus guideline to review and make 
recommendations for the assessment and management of ASD with a focus on drug 
treatments. We first review the aetiology of ASD to provide a framework to understand 
the diagnostic assessment of ASD and treatment targets. Subsequently we address 
the management of core symptoms, the management of common co-occurring 
conditions, non-pharmacological treatments, and the implications for service provision, 
before discussing future directions for clinical research. 
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3 Method 
A consensus meeting was held with the support of the British Association of 
Psychopharmacology (BAP) involving a group of experts on ASD in children, 
adolescents and adults. The group consisted of psychiatrists, psychologists, 
researchers in the field, and service user representatives. Members of the group gave 
presentations summarising each topic discussed in this paper, followed by discussion 
on the nature and quality of the evidence and its implications. Following the consensus 
meeting, a further literature review was conducted to support the consensus points. 
Drafts of the review and the recommendations were circulated to the expert group for 
comments, which were then revised by the expert group to derive the final version of 
the guidelines.  
 
The evidence in each area was rated using the criteria by Shekelle et al. (1999) 
(supplementary table 1), which rank meta-analyses of randomised controlled trials and 
large, representative observational studies as the best evidence. Our 
recommendations were graded based on the strength of the evidence supporting them 
using the grading criteria described in previous BAP guidelines (Bolea-Alamañac et 
al., 2014).  Thus, recommendations were rated A to D to reflect the evidence 
(supplementary table 1), with grade A indicating the recommendation is supported by 
the highest quality evidence. Although, some of the recommendations were based on 
weaker evidence (B, C, D), this does not necessarily reflect their clinical importance. 
The category S corresponds to a standard for clinical care, which comprises a 
consensus on good clinical practice in the absence of other evidence. In summarising 
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the pharmacological evidence, we have focused on the primary end-points of studies 
but, where this is not the case, we have indicated that the evidence is based on a 
secondary end-point. We have reported the doses used or, where the dose was 
variable, we have reported the mean dose used or range if the mean dose was not 
reported. We also summarise key aspects of the design of the study (whether the 
raters were blind to intervention, and whether the sample was randomised to a placebo 
or other comparator) and sample size (using the intention to treat sample) so that 
readers can gauge the strength of evidence.   
 
4 Aetiology 
4.1 Genetic risk factors 
Genetic factors play a substantial role in the aetiology of ASD. Recent studies have 
shown about 80% heritability for ASD (Lichtenstein et al., 2010; Ronald and Hoekstra, 
2011). However, within families, no one pattern of inheritance (e.g. autosomal 
dominant or recessive) is observed. With the exception of a small number of rare 
genetic variants (recently estimated at 71 (Sanders et al., 2015)), the effect of more 
common individual risk variants so far identified is small. Monogenetic syndromes with 
high rates of overlapping disorders which often include ASD as part of their behavioural 
phenotype include Phelan-McDermid Syndrome, Fragile X Syndrome and Tuberous 
Sclerosis (Ghosh et al., 2013). These constitute about 10-15% of all cases of ASD.  
 
In the majority of cases, the genetic risk for ASD is polygenic, involving multiple single 
nucleotide polymorphisms (SNPs), each of minor effect (Anney et al., 2012; Clarke et 
al., 2015; Klei et al., 2012; Gaugler et al., 2014). In addition to SNPs and monogenic 
disorders, a number of de novo suspected single gene loss of function mutations, and 
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copy number variants (CNVs; such as microdeletions or microduplications) spanning 
multiple genes have been reported to increase the risk of ASD and (often 
substantially), intellectual disability (de la Torre-Ubieta et al., 2016). Breakpoints 
consistently associated with ASD include the SHANK3 deletion, 1q21, 3q29, 7q11.23, 
15q11.2-13.1, 15q12, 15q13, 16p11, 17q12, 22q11.2, and Xq (Vorstman et al., 2006). 
 
The genetic risk variants for ASD implicate a number of key neurobiological pathways 
that are potential targets for drugs. Specific examples include the N-methyl-D-
aspartate (NMDA) 2B glutamate ionotropic and gamma-aminobutyric acid (GABA) 
receptors (including GABARA3 and GABARB3), cell adhesion molecules, scaffolding 
proteins such as SHANK1, SHANK2, SHANK3 ankyrin repeat domain proteins 
(Bourgeron, 2015), and neuron-glia signalling and microglial activation (de la Torre-
Ubieta et al., 2016). An improved understanding of the nature of the disruption in these 
pathways in ASD is needed to help develop targeted molecular therapies. 
 
4.2 Environmental risk factors 
A number of prenatal, perinatal and neonatal factors, including significant prematurity, 
perinatal hypoxia, maternal pre/perinatal infections (TORCH), maternal vitamin D 
deficiency, higher paternal age, gestational valproate exposure, maternal obesity and 
very low birthweight (<1500 gms), have been associated with an increased relative 
risk of ASD [for further details see reviews and meta-analyses: (Mandy and Lai, 2016; 
Gardener et al., 2011; Gardener et al., 2009; Eyles et al., 2013)]. Maternal use of 
SSRIs before or during pregnancy has also been identified in some studies, but 
significant questions have been raised about the causality of this association (Man et 
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al., 2015). Interestingly, preclinical work shows that some of these environmental risk 
factors impact on the same pathways implicated by the genetic association studies 
(Richetto et al., 2014; Basil et al., 2014), suggesting risk factors may converge on 
common pathways at the molecular or higher-level brain circuit levels (Voineagu et al., 
2011). 
 
4.3 Biology of ASD 
 
Brain structural differences in ASD have been identified early in life. The first studies 
examined head circumference and discovered that this proxy measure of brain size 
increased more in individuals with ASD than controls and their unaffected siblings 
during the first years of their life (Redcay and Courchesne, 2005; Constantino et al., 
2010; Elder et al., 2008; Courchesne et al., 2003). This is thought to be explained by 
a greater volume of both grey and white matter, with especially pronounced overgrowth 
in frontal and temporal cortex (Schumann et al., 2010). Early brain overgrowth may 
include an increase in cortical thickness in ASD at ages 3-4 years old, but seems to 
be followed by accelerated cortical thinning (Zielinski et al., 2014). Overall, the growth 
trajectory rate flattens in ASD such that, by the ages of 10-15 years old, average brain 
size in ASD is similar to typically developing children. Subsequently grey and white 
matter volumes may decrease in ASD in adulthood (Lange et al., 2015). However, it is 
noteworthy that not all head circumference or MRI volumetric studies support this 
model (Raznahan et al., 2013a; Raznahan et al., 2013b; Rogers, 2004; Hansen et al., 
2008). It is therefore possible that early brain overgrowth and subsequent growth 
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trajectory flattening is present in only a subset of individuals with ASD (Lenroot and 
KaYeung, 2013).  
 
Neurochemical alterations are also reported in ASD. One system repeatedly implicated 
is the serotonin system, which is thought to underpin some anatomical features of 
ASD. The serotonin system has a role in neurite outgrowth (Fricker et al., 2005), 
synaptogenesis (Mazer et al., 1997; Faber and Haring, 1999), differentiation and 
neurogenesis (Kesterson et al., 2002) and therefore its contribution to the early 
developmental aberrations reported in ASD is highly plausible. Serotonergic 
abnormalities in ASD include elevated serotonin levels in whole blood and platelets in 
upwards of 25% of affected individuals (Hanley et al., 1977; Gabriele et al., 2014) and 
alterations in the developmental trajectory of brain serotonin synthesis activity 
(Chugani et al., 1997). Together this evidence has provided a theoretical rationale for 
exploring the effect of serotonergic medications in ASD (Veenstra-VanderWeele et al., 
2012) (see section on co-occurring disorders).  
 
More recently, evidence for a pivotal role of the excitatory (E) glutamate and inhibitory 
(I) GABA systems in ASD has accumulated. An influential review by Rubenstein and 
Merzenich (2003) proposed that ASD is caused by an increased E/I ratio leading to 
pathological hyper-excitability within cortical circuits. Some preliminary support for the 
model comes from a PET study using a tracer that is relatively selective for the GABA-
A alpha-5 receptor sub-type, showing elevated GABA receptor availability in ASD, 
potentially indicating reduced GABA transmitter levels (Mendez et al., 2013). 
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Criticisms of the model include that it may be overly simplistic and not specific to ASD, 
as E/I imbalance has been implied in epilepsy and schizophrenia. E/I balance is likely 
to differ depending on the brain region and cell-type studied (Rothman et al., 2011; 
Rothman et al., 2012; Nelson and Valakh, 2015; Sibson et al., 1998). Furthermore, 
evidence from magnetic resonance spectroscopy (MRS) studies of glutamate and 
GABA in ASD has not been consistent. For example, a recent review of the MRS 
studies reported that out of the twelve studies in frontal cortical regions, four studies 
failed to report any differences between individuals with ASD and healthy controls; four 
studies (three in childhood and 1 adolescence) reported increased levels of glutamate 
and the combination of glutamate and glutamine (Glx), and one study reported reduced 
levels of Glx (Naaijen et al., 2015). In addition, three studies reported decreased levels 
of GABA in frontal regions (Naaijen et al., 2015). There are fewer studies in thalamus, 
hippocampus and striatum, although the results are similarly inconsistent (Naaijen et 
al., 2015). However, although informative, MRS is limited as it is an overall measure 
of tissue glutamate and/or GABA, which means intra-cellular levels may mask changes 
in synaptic levels. Thus, these inconsistencies may simply be a product of the current 
constraints of technology available to examine these neurotransmitters in the living 
human brain. However, they may also reflect the highly heterogeneous nature of ASD 
and/or pronounced differences between brain regions or developmental stages.  
 
In contrast preclinical studies have generated a much more consistent picture of E/I 
disruption in the perinatal period in rodent models relevant to ASD. In brief, animal 
models of ASD reveal an increase in spontaneous activity in sensory cortices in early 
life (Gonçalves et al., 2013; Gutierrez et al., 2009; Peixoto et al., 2016). This may at 
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least be partly a consequence of a ‘delay’ in the switch in GABA responses in brain 
from excitatory, during prenatal life, to inhibitory, during postnatal life in ASD and 
related conditions (Ben-Ari et al., 2012). 
 
Animal and clinical studies have shown that the neuropeptide oxytocin regulates social 
bonding and recognition, suggesting alterations in the oxytocin system could contribute 
to manifestations of ASD or its treatment (Baumgartner et al., 2008, Insel and Shapiro, 
1992, Domes et al., 2007, Ferguson et al., 2000). This has led to a number of clinical 
trials (see section on treatment of core symptoms). Furthermore, oxytocin modulates 
the switch from excitatory GABA to inhibitory function and is therefore an important 
regulator of E/I balance during the perinatal period (Tyzio et al., 2014; Tyzio et al., 
2006). It is likely that oxytocin continues to have a modulatory effect on E/I later in 
postnatal life. Hence oxytocin could serve as a target to modulate E/I balance in ASD. 
 
Lastly, increasing evidence from animal and clinical studies has agreed that a role for 
maternal and postnatal immune dysregulation in the aetiology of ASD cannot be 
overlooked. Taking into account the regulatory role that the immune system has on 
neuronal cells on every stage of brain development, it is plausible that immune 
dysfunction, caused by genetic mutations or environmental factors, could alter brain 
development and function (Estes and McAllister, 2015). Dysfunction of microglial cells, 
the resident brain immune cells, is one immune mechanism implicated in the 
pathogenesis of ASD. Data suggest that aberrant microglial function may lead to 
altered synaptic pruning, which may subsequently contribute to the pathogenesis of 
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ASD (Koyama and Ikegaya, 2015). However, not all in vivo evidence finds support for 
immunologic dysregulation (Pardo et al, 2015). 
 
4.4 Summary 
In conclusion, ASD is a complex neurodevelopment disorder that, in the majority of 
cases, shows multifactorial, polygenic inheritance, although de novo mutations and 
CNVs are currently estimated to play an important role about 10-20% of patients. 
Environmental factors, in particular early insults (prenatal, perinatal, and postnatal 
factors), also contribute to an increased risk of developing ASD. Brain development is 
disrupted from early childhood and shows alterations into adulthood. Key systems 
implicated in the pathophysiology of ASD are increasingly being identified and provide 
targets for clinical trials. These include (but are not limited to) the serotonin and 
oxytocin systems, the immune system and GABA / glutamate interactions.   
 
 
5 Diagnostic criteria 
5.1 DSM-5 
The Diagnostic and Statistical Manual version 5, published in 2013 (American 
Psychiatric Association, 2013), is the latest revision of the diagnostic criteria for ASD, 
and makes a number of changes to reflect recent research. The International 
Classification of Disease (ICD) version-10 (World Health Organization, 1992) is 
currently under review with a new revision, ICD-11, planned to be published in 2018. 
It is not yet clear to what degree ICD-11 will be aligned with DSM-5 – but it is likely 
there will be substantial agreement on core ASD characteristics. 
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The main features of the DSM-5 criteria for ASD are summarised in supplementary 
table 2. One key change is that the term ‘autism spectrum disorder’ (ASD) is used 
rather than the term ‘autism’ and its related categories used in DSM-IV (1994) and 
ICD-10 (e.g., Asperger Syndrome, Pervasive Developmental Disorder – Not Otherwise 
Specified (PDD-NOS), atypical autism). This shift acknowledges the lack of distinct 
neurobiological profiles between the different subtypes (Noterdaeme et al., 2010) and 
the inconsistency in their use (Lord et al., 2012a). The DSM-5 also includes a new 
category - Social (Pragmatic) Communication Disorder (SCD) - to describe individuals 
with deficits in social verbal and non- verbal communication, but who do not otherwise 
meet the criteria for a diagnosis for ASD because they do not show repetitive and 
restricted behaviours. As SCD was only recently introduced, its diagnostic reliability 
and validity, prognosis, and common features are still to be determined (Norbury, 
2014). 
 
The DSM-5 diagnostic criteria for ASD are broader than the DSM-IV criteria for autism. 
The previously separate domains of social interaction and communication under the 
DSM-IV classification have been unified as one domain in the DSM-5 (social 
communication). Hence the DSM-5 classification of ASD covers two domains; social 
communication difficulties and repetitive and restricted behaviours (supplementary 
table 1), and include abnormal sensory responses as a cardinal symptom (restored 
from the DSM-III). 
 
An important addition to DSM-5 is the inclusion of severity specifiers to indicate the 
impact of symptoms on adaptive functioning (supplementary table 3). Adaptive 
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functioning encompasses communication, occupation and daily living skills (Bal et al., 
2015).  As shown in supplementary table 3, there are three categories for each of the 
two core symptoms, indicating the level of support the affected individual requires, 
depending on his/her adaptive functioning.  This addition is undoubtedly crucial, as the 
severity of core symptoms and deficits in adaptive functioning may vary considerably 
between individuals with the disorder (Constantino and Charman, 2015). Another 
modification in DSM-5 is that the new diagnostic criteria offer the option to diagnose 
co-occurring psychiatric disorders.  
 
Another important change is that DSM-5 does not specify an age of onset, which has 
instead been revised to “symptoms must be present in the early developmental period 
(but may not fully manifest until social demands exceed limited capacities, or may be 
masked by learned strategies in later life)”. This recognises that ASD may not become 
fully apparent until later in life, and enables the diagnosis of ASD in adulthood (Howlin 
and Moss, 2012). In addition, DSM-5 does not require all symptoms to be currently 
present but rather specifies that they should have occurred at some point in the 
lifetime. This takes account of the observation that some symptoms are more common 
at certain time points and also that they may be less evident when the individual is in 
an optimal environment. 
 
A final change in DSM-5 is the introduction of clinical specifiers to be noted alongside 
the ASD diagnosis. These include the presence or absence of the following 
components: a) intellectual impairment, b) language impairment, c) known medical or 
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genetic condition or environmental factor, d) neurodevelopmental, mental of 
behavioural disorder, e) catatonia (American Psychiatric Association, 2013).  
 
Recent studies indicate that the overall prevalence of ASD may be lower under DSM-
5 compared to the prevalence of autism and related disorders based on the DSM-IV 
criteria (Maenner et al., 2014). This appears to be mostly due to ~20% of the 
individuals previously meeting the DSM-IV criteria for PDD-NOS not qualifying for a 
diagnosis of ASD according to DSM-5 criteria (Maenner et al., 2014; Mazefsky et al., 
2013; World Health Organization, 1992; Wilson et al., 2013). 
 
In summary, the DSM-5 criteria may be particularly useful for diagnosis as it enables 
diagnosis of adults whose symptoms were not impairing in childhood, and it highlights 
the importance of co-occurring disorders and functional impact. 
 
Consensus recommendations for diagnosis 
 
ASD is a complex neurodevelopmental disorder. Its diagnosis requires a developmental 
history. (B) 
 
It is recommended that established diagnostic criteria, such as DSM-5, are used for diagnosis. 
(D) 
 
Consider using the DSM-5 diagnostic criteria, as they enable diagnosis in adults and the 
diagnosis of co-occurring disorders. (D) 
 
Research needs 
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Further studies are required to evaluate the reliability and validity of the Social 
Communication Disorder diagnosis as a distinct disorder from ASD. (D) 
 
 
 
6 Assessment and diagnosis 
Making a diagnosis of ASD is a multi-stage process. It requires the multidisciplinary 
assessment of current symptoms, acquisition of a developmental history from a 
primary caregiver and the exclusion of alternative diagnoses by the clinician (National 
Institute for Health and Clinical Excellence, 2013) (evidence level IV).  
 
Symptoms can manifest and be interpreted differently depending on the environmental 
context. Thus, evaluation of symptomatology in different environments (home, school, 
community, in addition to the clinic) should be an expectation. The clinician should 
consider whether impairment in adaptive function is exclusively due ASD or an 
additional psychiatric or medical disorder (Constantino and Charman, 2015). The high 
prevalence of co-occurring disorders in ASD indicates that medical and psychiatric 
disorders, including intellectual ability, should be routinely screened for in individuals 
presenting with ASD (Kielinen et al., 2004; Simonoff et al., 2008b). In addition, 
cognitive, language and neuropsychological assessments may be considered, as they 
can provide valuable information about the individual’s strengths and weaknesses and 
inform the management plan (Charman and Gotham, 2013; Ozonoff et al., 2005). 
 
Reaching a diagnosis of ASD, particularly in adults, may be challenging for a variety 
of reasons. One of the key pillars of the diagnostic process is the acquisition of a 
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developmental history, preferably from a primary caregiver. However, informants for 
adults with a potential diagnosis of ASD may not be able to recall in detail the 
developmental history. In some instances, the primary caregivers may not be alive, so 
clinicians will need to rely on a history they obtain from other informants, and additional 
sources of information (such as school reports). Careful consideration should be given 
to the accuracy of retrospective recall and specific examples of behaviour should be 
elicited. Where no informant is available, diagnosis should be based on the history and 
current circumstances (including the current assessment, and reports from 
employment or school) (Lai and Baron-Cohen, 2015).  Similarly, the assessment of a 
non-verbal child with suspected ASD is also challenging with respect to accurate 
estimation of intellectual ability, social understanding, and co-occurring disorders. 
 
6.1 Instruments and diagnostic tools 
More than 20 screening and diagnostic tools for ASD have been developed over the 
last two decades (Charman and Gotham, 2013). The aim of screening tools is to 
identify individuals who are in need for further diagnostic assessment and evaluation. 
In the next section, we briefly summarize the most commonly used instruments used 
in childhood and adolescence (supplementary table 4 and 5), and in adulthood 
(supplementary table 6). 
 
A. Children 
In supplementary table 4, we provide a list of the most frequently used screening 
instruments for children who may have ASD. Supplementary table 5 summarises the 
structured diagnostic instruments for children who may have ASD based on a 
screening instrument or other information. The structured instruments vary from 
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observational measures (e.g. Autism Diagnostic Observation Schedule (ADOS) (Lord 
et al., 2012b) to caregiver interviews (e.g. Autism Diagnostic Interview Revised (ADI-
R) (Lord et al., 1994)) .  
 
B. Adults 
In supplementary table 6, we summarize the most common screening instruments for 
ASD in adults. Diagnostic tools for adults are summarized in supplementary table 5. 
The most robust observational measure for ASD diagnosis in adulthood is the ADOS 
(module 4)(Lord et al., 2000). However, it has limitations, including its relatively low 
sensitivity when used to diagnose higher functioning adults with ASD and low 
specificity in individuals with severe intellectual disability (when used without ADI-R) 
(Bastiaansen et al., 2011). It also may not fully capture repetitive behaviours and/or 
intense preoccupations (Kim and Lord, 2010) 
 
The development of assessment tools for ASD has helped increase the identification 
of ASD and aided accuracy of diagnosis both in clinical and research settings (Johnson 
and Myers, 2007). Clinicians and researchers should be aware of the strengths and 
limitations of the instruments. For example, being screened positive on one of the 
screening instruments does not mean that the individual meets a diagnosis for ASD; 
in the same way, being screened negative does not exclude the diagnosis of ASD. 
Results of the instruments differ depending on the setting, the presence of other mental 
disorders, the sample characteristics and the purpose of the screening (Charman and 
Gotham, 2013) (evidence level II). Other limitations include the requirement for trained 
administrators and raters and the time taken to administer them; which can be several 
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hours. One should also take into consideration that most of these tools have not been 
extensively validated in individuals with ASD and intellectual disability or non-western 
cultures (Rudra et al., 2014).  
 
Despite the acknowledged limitations of individual instruments, the use of a structured 
diagnostic instrument is still highly recommended in the evaluation of an individual with 
suspected ASD to ensure a comprehensive and systematic assessment. 
 
6.2 Diagnostic challenges 
Individuals with ASD may present to services with co-occurring psychiatric disorders, 
and ASD may be overlooked if it is not considered during the assessment (Lai and 
Baron-Cohen, 2015). Adults with ASD may develop adaptive mechanisms to manage 
social situations, for example by mimicking the gestures and conversational style of 
others (Lai et al., 2011) (evidence level II). This can mask the presentation and make 
the diagnosis more challenging (Lai et al., 2011). Another complication is that some 
studies have shown that core symptoms may be manifested differently in females than 
in males (Van Wijngaarden-Cremers et al., 2014), which may delay diagnosis in 
females (Wilson et al., 2016). For example, females with ASD may have restricted 
interests that involve people (literature, pop bands) rather than objects, such as 
collection of stamps or trains, as seen in males with ASD. They also may have fewer 
stereotyped behaviours and have more socially accepted interests (Van Wijngaarden-
Cremers et al., 2014; Mandy et al., 2012) (evidence level III). Females with ASD may 
be more likely to have developed coping strategies to manage social situations that 
mask the degree of their social isolation from peers (Dean et al., 2016). Females in 
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particular may demonstrate overt shyness or bossiness and being perfectionist. These 
characteristics constitute the so-called ‘female phenotype’ (Lai and Baron-Cohen, 
2015) (evidence level III), however they do not constitute core autistic symptoms and, 
importantly, may be present in people without ASD.  
 
Consensus recommendations for diagnostic process 
A multidisciplinary approach is recommended for the diagnosis of ASD. (D) 
 
The diagnostic process should involve a direct clinical assessment of the individual, and, 
wherever possible, a detailed interview with the caregiver or other informants, reports from 
school and employment, and assessment of cognitive and language skills and a medical 
examination. (D) 
 
Screening instruments are useful in aiding diagnosis, but should not be used exclusively to 
make or exclude the diagnosis. (B) 
 
Diagnostic challenges are more pronounced when diagnosis is made in adulthood, and extra 
care should be made to rule a diagnosis out. (B) 
 
It is recommended that ASD is routinely considered in the differential diagnosis when an 
individual presents to mental health services with a psychiatric disorder.  (D) 
 
Clinicians should be aware of the so-called female phenotype and a careful assessment in 
females is recommended. (C) 
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7 Prevalence of co-occurring mental health difficulties in ASD 
Co-occurring psychiatric disorders are highly prevalent in ASD and are more common 
in ASD than in the general population (Croen et al., 2015). Between 69 and 79% of 
individuals with ASD experience at least one additional psychiatric condition during 
their lifetime (Lever and Geurts, 2016; Buck et al., 2014), compared to rates of lifetime 
psychiatric disorder of approximately 40% in the general population (Bijl et al., 1998). 
 
7.1 Co-occurring difficulties in children with ASD  
Irritability, self-injurious behaviour and temper tantrums are amongst the most common 
co-occurring symptoms in children with ASD, seen in around 85% of both high and 
lower functioning children with ASD (Mayes et al., 2011). Anxiety is also common, and 
anxiety disorders are seen in children with ASD with prevalence rates of between 42% 
and 55% (Simonoff et al., 2008a; de Bruin et al., 2007). Of these, specific phobia 
(prevalence in ASD of between 9 – 44%) and social phobia (prevalence in ASD of 
between 8 – 29%) are the most common disorders (Simonoff et al., 2008a; de Bruin 
et al., 2007; Leyfer et al., 2006). Attentional/hyperactive and behavioural difficulties are 
also common in ASD. Between 28% and 53% of children with ASD meet criteria for 
ADHD and between 7% and 37% meet criteria for an oppositional defiant disorder or 
conduct disorder (Simonoff et al., 2008a; de Bruin et al., 2007; Leyfer et al., 2006; 
Sinzig et al., 2009; Salazar et al., 2015). Bipolar disorder and psychotic disorders are 
less common in ASD, but occur at rates above that of comparison groups (Croen et 
al., 2015). Mood disorders also often occur in children with ASD (Simonoff et al., 
2008a; de Bruin et al., 2007; Leyfer et al., 2006). This constellation of problems might 
also contribute to the sleeping difficulties, which parents report are a concern in 50% - 
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80% of children (Richdale and Schreck, 2009). What it is not clear, however, is to what 
extent these are part and parcel of an ASD diagnosis, or a component of the other 
conditions that children with ASD may experience. Moreover, the underlying 
mechanisms may be different to those in people without ASD, which would have 
implications for using treatments developed for these difficulties in people without ASD 
(Maskey et al., 2013).  
 
7.1 Co-occurring difficulties in adults with ASD  
Mood and anxiety disorders are also common in adults with ASD (Wigham et al., 
2017). Between 26 – 57% of adults with ASD experience a mood disorder at some 
point (Lever and Geurts, 2016; Croen et al., 2015; Roy et al., 2015b; Joshi et al., 2013; 
Hofvander et al., 2009), and anxiety disorders, particularly social phobia, are similarly 
common (Lever and Geurts, 2016; Croen et al., 2015; Roy et al., 2015a; Joshi et al., 
2013; Hofvander et al., 2009). ADHD is also frequently reported in adults with ASD, 
with prevalence rates of between 11 to 43% (Lever and Geurts, 2016; Croen et al., 
2015; Joshi et al., 2013; Hofvander et al., 2009). However, older adults with ASD have 
been reported to have lower rates of co-occurring psychiatric disorders than younger 
adults with ASD, and social phobia in particular appears to be significantly less 
common in this group (Lever and Geurts, 2016). Tic disorders and Tourette syndrome 
are also frequently reported co-occurring problems in adults with ASD. Between 20-
22% of children and adults with ASD meet criteria for a tic disorder (Canitano and 
Vivanti, 2007; Hofvander et al., 2009). 
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Together, these co-occurring disorders have a marked impact on functional 
impairment and caregiver burden, comparable to that reported by persons caring for 
individuals with a brain injury (Cadman et al., 2012). Thus, identifying and treating co-
occurring disorders in adults with ASD is critical; and this has been identified as a 
priority by health services and agencies (such as the UK Dept. of Health and the US 
Agency on Healthcare Research and Quality).  
 
8 Pharmacological Treatment of Core Symptoms of ASD 
In this section, we will initially summarise the results from studies of pharmacological 
treatments for the core symptoms of ASD (deficits in social communication and 
interaction, and restricted and repetitive interests or behaviours). We will then discuss 
the limitations of the evidence, and finally, proceed with recommendations. 
 
Two main approaches have been taken to develop pharmacological agents for ASD. 
One is re-purposing treatments from other psychiatric disorders that have symptoms 
in common with ASD. The second approach is to target the putative neurobiological 
processes underlying ASD, in some instances by targeting potentially more 
homogenous sub-populations, such as those with rare genetic abnormalities who have 
ASD, for example individuals with fragile X syndrome (FXS).  
 
In the following sections, we summarise results from the pharmacological studies 
grouped by the system primarily targeted, in children first and then adults. In this and 
the section on co-occurring conditions and symptoms, studies with less than 20 
participants in the intention to treat analysis are described as small, studies with 20-45 
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are described as medium, and those with more than 50 participants are described as 
large. An overview of study designs and findings is given in supplementary table 7. 
 
8.1 Serotonergic agents 
 
A number of trials of SSRIs have been undertaken but all bar one have involved small 
sample sizes and demonstrated mixed results (supplementary table 7). 
 
A small study of fenfluramine  was conducted in children with ASD (Barthelemy et al., 
1989) (evidence Ib).  Core symptoms were assessed using the Behavior Summarized 
Evaluation scale (Barthélémy, 1986). There was no significant difference from baseline 
or between the treatment and placebo groups. Reported side effects included 
withdrawal and sadness, and weight loss (Barthelemy et al., 1989). Fenfluramine is no 
longer marketed due to serious adverse effects and it is not recommended for use in 
ASD. 
 
One large study of citalopram evaluated its effect on repetitive behaviours in children 
with ASD and failed to demonstrate any significant improvement on the Clinical Global 
Impression (CGI) Improvement subscale, or on any secondary outcomes including the 
Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive 
developmental disorders (King et al., 2009) (evidence Ib). In addition, children on 
citalopram experienced significantly more adverse events than children given placebo, 
particularly increased energy levels, impulsiveness, decreased concentration, 
hyperactivity, increased stereotypy, diarrhoea, initial insomnia, dry skin, and in one 
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case a prolonged seizure (King et al., 2009). Citalopram is therefore not recommended 
for the treatment of core symptoms in children with ASD (evidence Ib). A medium size 
study of liquid fluoxetine was conducted in  children and adolescents with ASD 
(Hollander et al., 2005).   Using a low dose of fluoxetine, significant improvement was 
reported in repetitive behaviours as measured by the Children’s Yale-Brown 
Obsessive-Compulsive Scale (CY-BOCS), with an effect size of 0.76, but the overall 
reduction in repetitive behaviours was <10%. No significant differences between 
fluoxetine and placebo were reported for side effects (Hollander et al., 2005) (evidence 
Ib). However, another large completed but unpublished study registered on 
Clinicaltrials.gov of children and adolescents with ASD treated with fluoxetine was 
reportedly negative (evidence level Ib) (Neuropharm: clinicaltrails.gov, 2012).  
 
In contrast with studies in children, the studies in adults have been more consistent. A 
small study fluoxetine in six adults with ASD showed improvement in the CGI scale in 
three subjects (Buchsbaum et al., 2001) (evidence IIb double down-graded because 
of the small sample size). In addition, two small studies showed benefits for 
fluvoxamine and for fluoxetine on measures of repetitive behaviours for adults 
(McDougle et al., 1996; Hollander et al., 2012). However, the benefits were small 
relative to placebo and the evidence is limited by the small sample sizes (evidence Ib). 
Therefore, there is not sufficient data to support the recommendation for fluvoxamine 
or fluoxetine.  
 
A recent Cochrane review concluded that there is no evidence to support the use of 
serotonergic agents in children, whereas there are data to support their use in adults, 
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particularly for repetitive behaviours (Williams et al., 2013) (evidence Ia). Fluoxetine 
seems the best tolerated of the serotonergic agents, but it should be noted there have 
been no head to head comparisons of fluoxetine against other agents. 
 
 
8.2 Glutamatergic agents 
 
a) Metabotropic glutamate receptor 5 (mGLuR5) antagonists 
Animal models of fragile X syndrome (FXS) have shown that in the absence of fragile 
X mental retardation protein (FMRP), encoded by the FMR gene, there is an elevation 
of mGluR5 receptor levels (Dolen and Bear, 2008). Animal behaviours analogous to 
ASD symptoms are improved by mGluR5 antagonists (Silverman et al., 2014). Based 
on these findings, trials in FXS have focused on mGluR5 antagonists, such as 
AFQ056.  The first small- size study of AFQ056  did not find any statistically significant 
effect on the Aberrant Behaviour Checklist (ABC-C) (evidence level Ib), although a 
post hoc analysis suggested an improvement in the ABC- Social Avoidance subscale 
for a subgroup of patients based upon level of FMR1 methylation (Jacquemont et al., 
2011) (evidence level IIb). Moreover, recent results from two large studies failed to 
demonstrate any efficacy in the primary endpoint, the ABC-C, (Berry-Kravis et al., 
2016) (evidence level Ib) regardless of FMR1 methylation status. Although the authors 
of these studies suggested that further trials in a younger population with longer 
treatment duration are needed in order to fully test the mGluR5 theory (Berry-Kravis et 
al., 2016), the current evidence does not support the use of AFQ056 and the value of 
targeting mGluR5 in ASD appears in doubt, at least for people with FXS. 
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b) Memantine is an uncompetitive NMDA antagonist that has been used in dementia 
(Reisberg et al., 2003). Preclinical studies have shown that when synaptic glutamate 
levels are high, memantine blocks NMDA receptors, whereas it has the opposite effect 
when synaptic glutamate levels are low (Parsons et al., 2007). A small study of 
memantine (Erickson et al., 2007) suggested promising effects, as measured with the 
CGI scale, however a subsequent large study in children with ASD did not demonstrate 
any efficacy in either primary or secondary outcomes (evidence level Ib). Overall, the 
evidence does not support the routine use of memantine. 
 
c) D-cycloserine is a partial agonist at the glycineb site on NMDA receptors. Several 
studies have indicated that it is beneficial for the treatment of the negative symptoms 
of schizophrenia (Tsai and Lin, 2010). Based on the overlap between negative 
symptoms in schizophrenia and social withdrawal in ASD, Posey et al. (2004) 
conducted a small study in children with PDD. Results showed a significant 
improvement on the CGI and social withdrawal subscale of the ABC (Posey et al., 
2004) (evidence level Ib). A recent medium size study in children with ASD reported 
that D-cycloserine was superior to placebo at reducing Social Responsiveness Scale 
scores at 22 (Wink et al., 2017), but not 11 weeks (Minshawi et al., 2016) (evidence 
level Ib). Thus, while there are some promising results, the current evidence does not 
currently support the routine use of d-cycloserine. 
 
d) Amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptor 
modulators 
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CX516 is an allosteric positive modulator of AMPA receptors that has been trialled in 
fragile X syndrome (Berry-Kravis et al., 2006). CX516 binds to the AMPA receptor 
complex, and is thought to slow down the rate of receptor closing to promote long-term 
potentiation (LTP) in the hippocampus (Arai et al., 1996). However, a medium size in 
adults with FXS reported no significant effects on cognitive and behavioural outcome 
measures (Berry-Kravis et al., 2006) (evidence level Ib). Thus, the evidence does not 
currently support the use of CX516.  
 
a) metabotropic glutamate receptor 5 (mGLuR5) antagonists 
Animal models of fragile X syndrome (FXS) have shown that in the absence of fragile 
X mental retardation protein (FMRP), encoded by the FMR gene, there is an elevation 
of mGluR5 receptor levels (Dolen and Bear, 2008). Animal behaviors analogous to 
ASD symptoms are improved by mGluR5 antagonists (Silverman et al., 2014). Based 
on these findings, trials in FXS have focused on mGluR5 antagonists, such as 
AFQ056. The first double blind placebo controlled study of AFQ056 given for 4 weeks 
in 30 adults with FXS reported no statistically significant effect on the Aberrant 
Behaviour Checklist (ABC-C) (evidence level Ib), although a post hoc analysis 
suggested an improvement in the ABC- Social Avoidance subscale for a subgroup of 
patients based upon level of FMR1 methylation (Jacquemont et al., 2011) (evidence 
level IIb). Moreover, recent results from two parallel group double blind placebo 
controlled trials, one in 175 adults and one in 139 adolescents, failed to demonstrate 
any efficacy in the primary endpoint, the ABC-C, after 12 weeks’ treatment with 
AFQ056 (Berry-Kravis et al., 2016) (evidence level Ib) regardless of FMR1 methylation 
status. Although the authors of these studies suggested that further trials in a younger 
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population with longer treatment duration are needed in order to fully test the mGluR5 
theory (Berry-Kravis et al., 2016), the current evidence does not support the use of 
AFQ056 and the value of targeting mGluR5 in ASD appears in doubt, at least for 
people with FXS. 
 
b) Memantine is an uncompetitive NMDA antagonist that has been used in dementia 
(Reisberg et al., 2003). Preclinical studies have shown that when synaptic glutamate 
levels are high, memantine blocks NMDA receptors, whereas it has the opposite effect 
when synaptic glutamate levels are low (Parsons et al., 2007). A small open label study 
of memantine (Erickson et al., 2007) (mean dose=10.1 mg/day) suggested promising 
effects, however a subsequent large randomised controlled open label trial of in 121 
children (aged 6 – 12 years) with ASD was terminated early due to lack of efficacy 
(Aman et al., 2016)  (evidence level Ib). Overall, the evidence does not support the 
routine use of memantine. 
 
c) D-cycloserine is a partial agonist at the glycineb site on NMDA receptors. Several 
studies have indicated that it is beneficial for the treatment of the negative symptoms 
of schizophrenia (Tsai and Lin, 2010). Based on the overlap between negative 
symptoms in schizophrenia and social withdrawal in ASD, Posey et al. (2004) 
conducted a prospective single blind study in 12 children with PDD. This involved an 
initial 2-week placebo lead in phase, which was followed by a 6-week administration 
of d-cycloserine in three ascending doses (0.7, 1.4, and 2.8 mg/kg/day). Significant 
improvement on the CGI and social withdrawal subscale of the ABC was reported in 
the 10 participants who completed the 8-week study (Posey et al., 2004) (evidence 
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level Ib). However, results were not replicated in a subsequent double-blind placebo 
trial including 60 children with ASD (Minshawi et al., 2016) (evidence level Ib). Thus, 
the evidence does not currently support the routine use of d-cycloserine. 
 
d) Amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptor 
modulators 
CX516 is an allosteric positive modulator of AMPA receptors that has been trialled in 
fragile X syndrome (Berry-Kravis et al., 2006). CX516 binds to the AMPA receptor 
complex, and is thought to slow down the rate of receptor closing to promote long-term 
potentiation (LTP) in the hippocampus (Arai et al., 1996). However, a randomised 
double blind placebo controlled 4-week trial of CX516 (dose=300mg) in 49 adults with 
FXS reported no significant effects on cognitive and behavioural outcome measures 
(Berry-Kravis et al., 2006) (evidence level Ib). Thus, the evidence does not currently 
support the use of CX516.  
 
8.3 GABAergic agents 
GABAb agonists 
GABAb agonists such as arbaclofen activate GABA and preclinically inhibit the release 
of glutamate. Theoretically this should restore the balance of excitatory and inhibitory 
neurotransmission in ASD. Three trials have been conducted with arbaclofen to date, 
one in individuals with FXS and two in individuals with ASD. The first was a  medium 
size study in individuals with a full mutation of the FMR gene(Berry-Kravis et al., 2012).  
Although there was no difference in the primary outcome (ABC–Irritability subscale) 
(evidence level Ib), post hoc analysis showed significant improvements with arbaclofen 
in the ABC- Social Avoidance subscale (evidence level IIb). The second study was a 
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medium size study in children and young people with either ASD, PDD or PDD-NOS 
(Erickson et al., 2014). The results showed significant improvement on the primary 
outcome, ABC-Irritability scale, as well as in the Lethargy/Social Withdrawal subscale 
(Erickson et al., 2014; Berry-Kravis et al., 2012) (evidence level IIb).  In a   recent large  
study in children and young people with ASD (Veenstra-VanderWeele et al., 2016) 
(evidence level Ib),   there was no significant change in the primary outcome, the ABC-
Social Withdrawal Scale, but there was an improvement in secondary outcomes 
including on the CGI Severity and Improvement scale, and the Socialization and 
Communication subscales of the Vineland Adaptive Behavior Scale (VABS) 
(Veenstra-VanderWeele et al., 2016). 
 
Overall, there is a lack of evidence to recommend the routine use of arbaclofen. Further 
studies are needed to evaluate this further and examine sub-groups (Brondino et al., 
2016). 
 
Pregnenolone is a neurosteroid that acts as a positive allosteric modulator of GABAA 
receptors to enhance GABAA receptor function (Hosie et al., 2006). A previous 
functional neuroimaging study in healthy volunteers reported that compared to 
placebo, administration of a single oral dose of 400 mg pregnenolone was associated 
with increased connectivity between the amygdala and medial prefrontal cortex, and 
reduced self-reported anxiety (Sripada et al., 2013). Subsequently a  small study was 
conducted in adults with ASD (Fung et al., 2014). Among the secondary outcome 
measures, there was a significant improvement in the ABC- lethargy/social withdrawal 
scale (evidence level IIb).  However, the study has a number of limitations, including 
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the small sample size, open-label design and absence of a placebo group (Fung et al., 
2014), which means it is premature to base recommendations on this study. Therefore, 
large scale, placebo-controlled randomized trials are necessary to test the benefit of 
pregnenolone further before it can be recommended in clinical practice. Until then, 
pregnenolone is not recommended. 
 
8.4 Dopamine receptor blockers (antipsychotics) 
 
a) Risperidone: Risperidone is a D2 dopamine receptor subtype antagonist and is 
one of the only two approved medications by the EMA/FDA for the treatment of 
irritability in ASD. Several trials have also measured core symptoms of ASD. 
Secondary analysis (McDougle et al., 2005b) from the RUPP study ((McCracken et al., 
2002b) has shown significant decreases in repetitive behaviours with moderate effect 
sizes (Cohen’s d= 0.55), as measured with CY-BOCS scale, and paralleled by 
decreases in ABC-Stereotypy subscale scores with large effects (Cohen’s d= 0.8) 
(evidence level IIa (downgraded from Ib because it is based on secondary analyses). 
In a post hoc analysis of RUPP and RUPP2 (Aman et al., 2009; McCracken et al., 
2002b) risperidone studies, significantly greater decreases in ABC-Lethargy/Social 
Withdrawal and hyperactivity subscale scores were observed in the risperidone- 
versus placebo-treated subjects (Scahill et al., 2013) (evidence level IIb). Common 
side effects reported in the studies included weight gain, elevated prolactin levels, and 
sedation (seen in 37% of subjects), although sedation subsided after 8 weeks of 
treatment (Aman et al., 2005a).  
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b) Aripiprazole: Aripiprazole is a D2 dopamine receptor subtype antagonist with some 
partial agonist properties (Kim et al., 2013). It is FDA approved for irritability in ASD. It 
has been examined in ASD primarily to treat irritability, but secondary analyses have 
investigated effects for core symptoms. A recent Cochrane review of aripiprazole for 
ASD concluded that evidence from two RCTs suggested that it was effective as a short 
term medication for some behavioural aspects of ASD (Hirsch and Pringsheim, 2016). 
Significant improvements on the ABC- Stereotypy scale and CY-BOCS were reported 
from a large study in children and adolescents with ASD (Marcus et al., 2009) 
(evidence level IIa) (down-graded because this was not the primary outcome 
measure). In addition, a post hoc analysis that combined this study with another study 
(Aman et al., 2010; Owen et al., 2009) showed a significant improvement in the ABC 
stereotypic behaviour subscale scores, with greatest change on the item for repetitive 
hand, body or head movement (Aman et al., 2010) (evidence level IIa). The most 
common side effects reported were sedation (20%) and somnolence (10%) (Aman et 
al., 2010) 
 
Taken together, the studies of dopamine receptor blockers provide evidence that these 
agents may be beneficial for the treatment of repetitive behaviours in ASD (evidence 
level IIa). However, there are some caveats: the outcome measures used do not 
differentiate between compulsions and stereotyped behaviours, the observed 
differences versus placebo were modest (20%), and the trials were short, hence there 
is no evidence to indicate if benefits are maintained. Furthermore, the level of clinical 
benefit due to reduction in these behaviours was not determined and the patient 
populations were all selected because of high levels of irritability, rather than high 
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levels of repetitive behaviours. Overall, in view of the potential risk of adverse effects, 
it is not recommended that they are routinely used to treat repetitive behaviours. If they 
are used, a clear treatment goal should be agreed and a plan to measure this put in 
place; the risks and benefits should be carefully re-evaluated at regular intervals to 
ensure the balance continues to favour treatment. Furthermore, dosages should start 
small and build up over time. 
8.5 Other approaches 
 
Methylphenidate: Jahromi and colleagues conducted a 4-week randomised, double-
blind crossover sub-study of placebo in children with PDD and high levels of ADHD 
symptoms (Jahromi et al., 2009), as a part of a larger methylphenidate ASD trial (see 
below). Observational measures assessing social communication and self-regulation 
were recorded at each medication dose.  
 
Sub-analysis of data from a larger methylphenidate ASD trial (Research Units on 
Pediatric Psychopharmacology (RUPP) Autism Network, 2005) in children with 
symptoms of ADHD reported dose-dependent improvements in joint attention and self-
regulation (Jahromi et al., 2009). There was a moderate effect size (Cohen’s d=0.49) 
benefit for the best dose versus placebo for joint attention initiations and a moderate-
large effect size (Cohen’s d=0.61) for regulated affective state scores (Jahromi et al., 
2009)(evidence level Ib). It is unclear whether these results are mediated by 
improvement in ADHD symptoms. Moreover, there is no theoretical reason to expect 
these findings generalize to individuals with ASD who do not have high levels of ADHD 
symptoms. 
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Oxytocin: Evidence from genetic and preclinical studies suggests that oxytocin plays 
a role in social recognition, attachment, and stereotyped behaviours (Insel et al., 1999; 
Carter, 1998).  
 
A small pilot study of intranasal oxytocin was conducted in adults with ASD 
(Anagnostou et al., 2012). This study reported no significant changes in the primary 
outcome measure (the Diagnostic Analysis of Nonverbal Accuracy and Repetitive 
Behaviour Scale Revised). However, there were significant changes in secondary 
outcomes, specifically the reading the mind in the eyes test, a measure related to social 
communication, and a quality of life questionnaire (Anagnostou et al., 2012). A further 
small   study in adults with ASD reported a significant improvement in social reciprocity, 
as assessed by the ADOS. The effect size was large (Cohen’s d= 0.78), and 
improvement was correlated with increased functional connectivity between the 
anterior cingulate cortex and medial prefrontal cortex (Watanabe et al., 2015) 
(evidence level Ib). Results from studies in children and young people are also 
inconsistent. Guastella et al. (2015) conducted a medium size study in adolescent 
male individuals with ASD (evidence level Ib). Results did not suggest any clinical 
efficacy in  primary outcomes including change in the Social Responsiveness Scale as 
rated by caregivers and the clinician rated CGI-Improvement Scale. (Guastella et al., 
2015) (evidence level Ib). A recent medium size study with intranasal oxytocin in young 
children showed significant improvement in the primary outcome of caregiver-rated 
social responsiveness (Yatawara et al., 2016) (evidence Ib). 
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In summary, the evidence for oxytocin shows some promise, but also inconsistencies, 
with the largest study failing to find clear benefits. Moreover, direct replications are 
lacking due to studies using different outcome measures. There are also few findings 
of improvements that directly relate to real world function.  Additionally, little is known 
about the side effects of longer-term exposure to oxytocin (Okamoto et al., 2016). In 
sum, further studies are required to fully investigate oxytocin before it can be 
recommended for routine use.  
 
8.6 Recommendations 
 
Overall, the evidence is currently too limited to support the routine use of any of the 
agents discussed above for the core symptoms of ASD. Although risperidone and 
aripiprazole have both shown modest efficacy for the management of repetitive 
behaviours (evidence level IIa), these studies focussed on individuals with high levels 
of irritability and it is unclear whether the findings would generalize to the wider ASD 
population. Furthermore, side effects should be carefully considered. Oxytocin has 
shown some encouraging preliminary results for deficits in social cognition (evidence 
level Ib), although large scale randomised clinical trials for assessment of benefits for 
clinical outcomes and functioning and side effects of long-term exposure are 
warranted. 
 
8.7 Clinical Trials for ASD core symptoms in progress 
There are at least 12 active studies of oxytocin currently underway and there is also 
one large phase 2 study of vasopressin in children with ASD (NCT01962870). Insulin 
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Growth Factor-1 (IGF-1) is another promising target. Based on findings from preclinical 
studies, where it has been shown that IGF-1 ameliorates synaptic and behavioural 
deficits in SHANK-3 deficient mice (Bozdagi et al., 2010; Bozdagi et al., 2013), 
Kolevzon et al conducted a small-scale feasibility study of IGF-1 treatment in nine in 
children with Phelan-McDermid syndrome (PMS). Interestingly this showed a 
statistically significant improvement in social impairment and restrictive behaviours 
(Kolevzon et al., 2014). Currently a large study on IGF-1 is taking place in children with 
ASD (NCT01970345), and the results of this, and further work on the potential long-
term effects of IGF-1, are awaited. 
 
Consensus recommendations of pharmacological management of core 
symptoms 
Evidence from clinical trials to date has not demonstrated clear efficacy for the use for any 
agent in the routine management of ASD core symptoms. (S) 
 
 
There is some evidence for the use of risperidone and aripiprazole in the management of 
repetitive behaviours, but in view of the potential adverse effects, routine use is not 
recommended for treating repetitive behaviours. If used, clinicians should weigh up the risks 
and benefits and re-evaluate these regularly. (B) 
 
 
 
 
 
 
In the next sections, we summarise the results from studies of pharmacological 
treatments for co-occurring conditions and symptoms in ASD, discuss the limitations 
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of the evidence, and finally, proceed with recommendations. As many co-occurring 
conditions and symptoms vary by age, we discuss findings in children separately 
(section 9) from findings in adults (section 10). An overview of study designs and 
findings is given in supplementary table 8. 
 
9 Pharmacological treatment of co-occurring conditions and symptoms in 
children with ASD 
 
 
9.1 Treatment of depression in children with ASD 
Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are widely 
prescribed for people with ASD (Coury et al., 2012). However, there have been no 
rigorous studies that have investigated the role of SSRIs in treating mood disorders in 
children with ASD. Given the lack of direct evidence for SSRIs in ASD, the use of 
SSRIs to treat depression is therefore based on extrapolation from trials in patients 
without ASD (see BAP guidelines on major depression for recommendations) Cleare 
et al. (2015). An additional consideration is the evidence of increased sensitivity to side 
effects of SSRIs (see chapter on pharmacological treatments of core symptoms) seen 
in children with ASD (King et al., 2009) (evidence level Ib). We therefore recommend 
that SSRIs should be used in low doses and titrated up gradually and monitored 
carefully for side-effects. 
 
9.2 Treatment of anxiety and OCD in children with ASD 
Although pharmacological treatment of anxiety disorders has not been studied 
specifically in ASD, symptoms of obsessive-compulsive disorder (OCD) and anxiety 
have been investigated in a number of trials.  
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Risperidone: A medium size trial in participants with ASD and high levels of irritability 
at two dose ranges (lower =0.125 -0.175 mg/day; higher = 1.25 -1.75 mg/day) found 
improvement in OCD symptoms only in the high dose group (Kent et al., 2013) 
(evidence level IIa). Similarly, a large study reported significant, albeit modest, 
improvements in OCD symptoms after risperidone treatment at 2mg/day (McDougle 
et al., 2005a). 
 
In addition to improving symptoms of OCD, there is also evidence that risperidone may 
be effective at treating general symptoms of anxiety in ASD too. A medium size trial of 
risperidone in participants with ASD and high levels of irritability reported significant 
improvement relative to placebo on the insecure/anxious scale of the Nisonger Child 
Behavior Rating Form (N-CBRF) (parent version) (Shea et al., 2004) (evidence level 
IIa). However, it should be noted that a 16-week open-label study of 26 ASD child 
responders to risperidone reported increased anxiety in the mild-moderate range as a 
side-effect of treatment (Troost et al., 2005) (evidence level IIa). 
 
Clomipramine: One small study that investigated clomipramine in children with ASD 
reported a significant improvement in OCD symptoms (Gordon et al., 1993) (evidence 
level IIa). However, cardiovascular side effects of clomipramine can be significant, and 
reports of treatment-emergent seizures have been noted (Pacher and Kecskemeti, 
2004; Alldredge, 1999). 
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SSRIs: Two large studies have reported no effect of SSRIs (citalopram and fluoxetine) 
on obsessive-compulsive symptoms (King et al., 2009; Hollander et al., 2005). Neither 
drug was effective at reducing symptoms of OCD (evidence level IIa). 
 
Overall, there is little or no evidence for treating anxiety or OCD symptoms with 
risperidone, clomipramine or an SSRI. The studies of risperidone are limited to 
participants with high levels of irritability and did not select participants on the basis of 
clinically significant anxiety or OCD symptoms. Hence it is unclear whether any 
positive effects are clinically meaningful or pertain to those with co-occurring 
anxiety/OCD.  The same applies to studies of SSRIs, although here the combined 
evidence failed to identify an effect on anxiety or OCD symptoms. In view of the limited 
evidence, we recommend cautiously following the BAP guidelines for treating anxiety 
and OCD (Baldwin et al., 2005). 
 
9.3 Treatment of sleep problems in children with ASD 
 
Melatonin: A meta-analysis of five small studies supports the use of melatonin for 
sleep disorder in ASD (Rossignol and Frye, 2011) (evidence level Ia). Sleep duration 
was increased (the mean increase was 73min versus baseline and 44min versus 
placebo) and sleep onset latency decreased (mean decrease of 66min compared with 
baseline, and in comparison with a 39min decrease with placebo.) However, there 
were no changes in night-time awakenings in children with ASD (Rossignol and Frye, 
2011). The length of melatonin usage in these studies ranged from 14 days to over 
four years. Melatonin use was associated with minimal to no side effects. A further 
large study reported a small increase in total sleep time (by a mean of 22 minutes) and 
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an improvement in sleep onset (with a mean improvement of 38 minutes), though 
waking times became earlier too (Gringras et al., 2012). There is also evidence that 
melatonin combined with CBT is superior to melatonin only, CBT only and placebo in 
reducing symptoms of insomnia (Cortesi et al., 2012). The combination group also had 
a greater proportion of treatment responders reaching clinically significant 
improvements and fewer dropouts after 12 weeks (Cortesi et al., 2012) (evidence level 
Ib). Thus, overall, melatonin has proven to be an effective and well-tolerated drug in 
treating sleeping problems in children with ASD. Adding a behavioural intervention 
may be of additional value, at least in the short term.  
 
9.4 Treatment of irritability in children with ASD 
Common irritability symptoms seen in children with ASD include severe tantrums, 
aggression or self-injurious behaviours. It is important to note that irritability is more 
common in individuals with ASD and a co-occurring mood or anxiety disorder (Mayes 
et al., 2011). It is therefore important to consider and treat, if warranted, any co-
occurring mood or anxiety disorder.  
 
Risperidone was the first antipsychotic to receive approval by the USA Food and Drug 
Administration (FDA) for irritability in ASD (Food and Drug Administration, 2006). It has 
been widely studied, with evidence from 10 RCTs reporting its efficacy (evidence level 
Ib). Several small studies have reported reductions in irritability with large effect sizes 
(0.7 - 1.03) (Shea et al., 2004; Kent et al., 2013). Similarly, a large multi-site study 
reported a 57% reduction in irritability (effect size=1.2) (McCracken et al., 2002a). The 
most commonly reported side effects of risperidone were weight gain, increased 
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appetite, fatigue, drowsiness and drooling. Long term (six-month) use of risperidone 
has been investigated by two small studies. Risperidone appears to be tolerated 
reasonably well but long-term (6 months) use was associated with persistent side-
effects, including increased appetite, weight gain, mild sedation, hypersalivation and 
hyperprolactinaemia (Luby et al., 2006; Nagaraj et al., 2006) (evidence level Ib). 
Hyperprolactinaemia, which is potentially caused by a blockade of dopamine receptors 
in the tubero-infundibular system (Howes et al., 2009), may normalise over the long-
term (Findling and McNamara, 2004), however there is also evidence of increased 
prolactin after six-months of treatment (Luby et al., 2006). In comparison to haloperidol, 
risperidone seems to be better tolerated with a smaller sedative effect and a lower risk 
of extrapyramidal symptoms (Miral et al., 2008). 
 
Aripiprazole has also been approved by the FDA for the treatment of irritability in 
children with ASD (Waknine, 2010) and its effects studied in several RCTs. This 
evidence has been meta-analysed by Douglas-Hall et al. (2011) which reported a 
significant reduction in irritability relative to placebo with an effect size of 0.64 after 
eight weeks of treatment (evidence level Ib (down-graded because this study included 
only 2 RCTs (total n=316, dose range = 2-15mg/day). Similar to risperidone, side-
effects of aripiprazole included sedation, fatigue, and increased appetite. Vomiting was 
also reported by some children. It is also noteworthy that no increase in serum prolactin 
was observed in the aripiprazole studies and reductions were seen in some children. 
This suggests that aripiprazole is preferable to risperidone in cases with concerns 
regarding hyperprolactinaemia. A line-item analysis of the ABC-I from the two RCTs 
revealed that aripiprazole had no effect on self-injurious behaviour, which was 
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attributed to low baseline rates (Aman et al., 2010). Thus, although the construct of 
irritability includes self-injury, aripiprazole may not be helpful specifically for this 
symptom. A similar item analysis has not been performed for risperidone so it is 
unclear how this drug compares for self-injury.  
 
A large long term study of aripiprazole reported that the benefits of aripiprazole on 
irritability were maintained over the study period (Marcus et al., 2011). However, 
discontinuation due to side effects occurred in about 10%, with aggression and weight 
increase the most commonly reported. No additional safety concerns were identified 
besides those evident in short-term exposure. Therefore, both risperidone and 
aripiprazole appear to retain most of their initial benefits on irritability seen in acute 
studies, and both agents are suitable for longer periods of treatment, with appropriate 
routine safety monitoring. 
 
In conclusion, there is a reasonable body of evidence indicating that risperidone and 
aripiprazole are effective at treating irritability in ASD with moderate to large effect 
sizes. However, their potential benefits should be weighed against the risk of side 
effects. Behavioural and/or educational interventions should be considered prior to 
prescribing these drugs, given their side effect profiles. It is recommended that if an 
antipsychotic is started, treatment targets should be set and progress against these 
regularly evaluated, and weighed against side-effects (including relevant medical 
assessments and lab tests) during treatment reviews. In view of the risk of persistent 
side-effects, we also recommend periodic attempts to reduce the daily dosage and 
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discontinue to either confirm the necessity for on-going exposure, or establish that the 
need for the drug has resolved.  
 
9.5 Other approaches to treating irritability in children with ASD 
 
Minocycline has been investigated in an open label add-on pilot study of individuals 
with FXS (Paribello et al., 2010). Minocycline significantly reduced irritability ratings 
and improved secondary outcome measures, including the CGI-I (average score 
“mildly improved”) and a visual analogue scale (VAS) for behaviour (Paribello et al., 
2010) (evidence level IIb). The most common side effects were dizziness and 
diarrhoea. A medium sized trial also in subjects with FSX reported a modest 
improvement (2.49 versus 2.97, minocycline versus placebo respectively) on CGI-I 
ratings, but not in any of the secondary outcomes including the ABC–C scale (Leigh 
et al., 2013) (evidence level Ib). Overall, minocycline’s potential benefit for reducing 
irritability needs additional study before routine use can be recommended, particularly 
in non-FSX ASD populations. 
 
Arbaclofen has been studied in children with ASD for irritability with inconsistent 
findings to date. One open label study reported significant improvement on irritability 
ratings (Erickson et al., 2014) but two medium and large controlled trials reported no 
change on irritability ratings (Berry-Kravis et al., 2012; Veenstra-VanderWeele et al., 
2016)  (evidence level Ib).  
 
Amantadine is a non-competitive NMDA antagonist. Despite encouraging case 
reports and small open-label studies, a small controlled trial by King et al. (2001) 
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reported no effect of amantadine on responder rate or irritability ratings (evidence Ib). 
However, there were significant (albeit, modest) differences in clinician ratings for 
hyperactivity (amantadine reduction of –6.4 versus placebo reduction of –2.1) and 
inappropriate speech (amantadine reduction of –1.9 versus placebo reduction of 0.4) 
(King et al., 2001) (down-graded to evidence level IIa as a secondary analysis). No 
parent reported measures were identified as being significantly different. Thus, current 
evidence does not support the use of amantadine for irritability.  
 
In view of the limited data available for minocycline, randomised, double blind 
controlled studies are required before recommendations can be made. The current 
evidence does not support the use of arbaclofen or amantadine for irritability. 
 
9.6 Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and 
hyperactivity symptoms in children with ASD 
 
Methylphenidate has been reported as an effective treatment for ADHD in children 
with ASD by a meta-analysis of four studies (effect size= 0.67) (evidence level Ia, but 
note this is based on only 4 studies) (Reichow et al., 2013). A variety of different ADHD 
outcome measures were used in these studies and the duration of exposure ranged 
between one to four weeks (see table N). There is also evidence that the response 
rate to methylphenidate in individuals with ASD and ADHD is lower than in individuals 
with ADHD without ASD. For example, one medium size study reported a response 
rate of 50% in ASD subjects with symptoms of ADHD (Research Units on Pediatric 
Psychopharmacology Autism Network, 2005) compared to response rates of 70-80% 
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in children with ADHD without ASD (Jensen, 1999). The severity of side-effects may 
also be greater in individuals with ASD and ADHD compared to individuals with ADHD 
without ASD. Discontinuation rates due to side effects were much higher in the ASD 
study (18%) compared to the non-ASD study (1.4%) (Research Units on Pediatric 
Psychopharmacology Autism Network, 2005; Jensen, 1999). The most commonly 
reported side effects in children with ASD were decreased appetite, sleeping 
difficulties, abdominal discomfort, social withdrawal, irritability and emotional 
outbursts, mostly similar to those seen in the treatment of ADHD for people without 
ASD.  Taken together, these findings suggest that, although effective, methylphenidate 
may not be as effective in people with ASD as in people with ADHD and that individuals 
with ASD are more likely to experience side-effects. 
 
Atomoxetine, a non-stimulant drug for ADHD is an alternative to methylphenidate. 
Evidence from one small and one medium study demonstrate improvement in 
symptoms of hyperactivity but not inattention (Hedge’s g=0.83, effect size d=0.90) 
(Harfterkamp et al., 2012; Arnold et al., 2006) (evidence level Ib). The most common 
side effects were nausea, fatigue and sleeping difficulties (Arnold et al., 2006). A 
further large study investigated individual and combined-effectiveness of atomoxetine 
and parent training (PT). Atomoxetine, (both alone and combined with PT) significantly 
reduced ADHD symptoms (Handen et al., 2015). The authors conducted a 24-week 
extension study demonstrating that atomoxetine combined with PT was superior at 
reducing ADHD symptoms than atomoxetine alone (Smith et al., 2016). The effect 
sizes reported in the atomoxetine studies (0.59 – 0.98) are similar to the effect size 
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reported for methylphenidate in children with ASD (0.67) (Research Units on Pediatric 
Psychopharmacology Autism Network, 2005), suggesting equivalent efficacy. 
 
The α2A receptor agonist antihypertensive-drugs clonidine, guanfacine and 
lofexidine have also been examined as treatments for ADHD in children with ASD.  
 
Clonidine: two small studies have reported improvements in symptoms ADHD - in 
particular, symptoms of hyperactivity (Fankhauser et al., 1992; Jaselskis et al., 1992) 
(evidence level IIa down-graded because of the small sample sizes). Reported side-
effects included sedation, drowsiness, fatigue and decreased activity. Guanfacine 
appears to be less sedating than clonidine with promising evidence for its efficacy 
according to two studies (one small, one medium) (Scahill et al., 2006; Scahill et al., 
2015) (evidence level Ib). The study authors report a response rate of 50%, which is 
comparable to the group’s earlier methylphenidate response rate of 48% (Research 
Units on Pediatric Psychopharmacology (RUPP) Autism Network, 2005). Notable side-
effects included drowsiness, irritability, reduced blood pressure, and bradycardia. 
There is some preliminary evidence for lofexidine based on one small, non-randomised 
study, which reported significant improvement in ADHD (in particular, hyperactivity) 
(Niederhofer et al., 2002), but this is insufficient evidence to support routine use 
(evidence level Ib). 
 
In summary, there is good evidence that methylphenidate is an effective treatment for 
co-occurring ADHD in children with ASD. Atomoxetine should be considered as a good 
alternative to methylphenidate. There is also promising evidence for α2A receptor 
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agonists, which should also be considered as alternatives amongst those who are not 
responsive or intolerant to this class of medication. Reports suggest that risperidone 
and aripiprazole significantly improve scores on the ABC-H relative to placebo, 
suggesting these drugs may also be useful. Further studies are required in samples of 
ASD+ADHD to confirm their effectiveness, since the samples were not selected for 
ADHD and the ABC-H was not the primary outcome measure. Treatment effect sizes 
are generally lower in ASD than typically developing populations, and, at least for 
stimulants, levels of adverse effects are higher. Close periodic monitoring of side 
effects (including relevant medical assessments) is thus of high importance where 
these treatments are used in ASD. 
 
10 Pharmacological treatment of co-occurring conditions and symptoms in     
adults with ASD 
 
10.1 Treatment of depression in adults with ASD 
The evidence for treating mood disorders in adults with ASD is very limited. Only one 
SSRI (fluoxetine) has been studied in adults with ASD, with no change in depression 
relative to placebo (Buchsbaum et al., 2001) (evidence level IIa). Secondary analysis 
of risperidone in a trial for repetitive behaviours demonstrated significant reductions on 
a visual analogue scale for mood in a non-clinically depressed group (McDougle et al., 
1998). The efficacy of risperidone for clinical depression in ASD remains to be tested. 
 
Given the limited evidence-base of studies in ASD groups, we recommend following 
the British Association for Psychopharmacology (BAP) guidelines for treating 
depression in ASD (Cleare et al., 2015). These should be applied cautiously given the 
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apparent increased propensity for behavioural activation associated with 
antidepressants in youth with ASD and that these guidelines are not specific to people 
with ASD (Vasa et al., 2014). 
 
10.2 Treatment of anxiety and OCD in adults with ASD 
Evidence for treating anxiety in adults with ASD is also limited and studies have been 
mainly focused on obsessive/compulsive symptoms.  
 
Fluoxetine has been studied for anxiety in ASD in two small studies. One reported a 
significant improvement in obsessions but not compulsions (Buchsbaum et al., 2001) 
(evidence level IIa) and the other reported a significant reduction in self-reported 
compulsions (Hollander et al., 2012) (evidence level Ib). No change in compulsions 
was found in ratings by independent observers. 
 
Fluvoxamine has been reported to reduce symptoms of both obsessions and 
compulsions by one small study at eight and 12 weeks (McDougle et al., 1996) 
(evidence level Ib).  Apart from nausea and mild sedation in a few patients, fluvoxamine 
was well tolerated.  
 
Risperidone was reported to reduce symptoms of anxiety/nervousness on a clinician 
rated visual analogue scale and self-reported compulsions in a study of repetitive 
behaviours in ASD (McDougle et al., 1998) (evidence level Ib). The participants all 
scored above 10 on the Y-BOCS compulsion subscale at entry, indicating at least mild 
severity at baseline. 
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In summary, benefits have been reported in small studies using SSRIs as a treatment 
for anxiety disorders, predominantly OCD, in adults with ASD. Although SSRIs are 
generally well tolerated, the beneficial effects are modest, and the evidence is limited. 
There is currently insufficient evidence to recommend risperidone. In view of the limited 
specific evidence in ASD, we therefore recommend following the BAP guidelines for 
treating anxiety (Baldwin et al., 2005), but, as with the treatment of mood disorders, 
we would recommend proceeding cautiously. 
 
10.3 Treatment of sleep problems in adults with ASD 
Despite the evidence for its effectiveness in children with ASD, there are currently no 
published clinical trials of melatonin in adults with ASD. One small (n=6) retrospective 
study reported that melatonin was effective in reducing sleep onset latency and 
nocturnal awakenings and improved total sleep time (Galli-Carminati et al., 2009) 
(evidence level III). Effects remained after 6 months and no side effects were noted 
during the therapy. 
 
Given the limited evidence, recommendations must be made by extrapolation from 
studies in children and adults without ASD. We recommend following the BAP 
guidelines on sleep disorders (Wilson et al., 2010) with the same general caveats 
discussed for mood and anxiety disorders. In addition, it is worth considering an early 
trial of melatonin, in view of the benefit in children, and its favourable side-effect profile. 
We do not recommend the prolonged use of benzodiazepines and related GABA 
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agonists due to the risk of tolerance and side-effects, in line with the BAP guidelines 
on sleep disorders. 
 
10.4 Treatment of irritability in adults with ASD 
Treating irritability has been less well studied in adults than it has been in children with 
ASD.  
 
Risperidone was reported to significantly reduce symptoms of irritability and 
aggression in a small study after 12 weeks (McDougle et al., 1998) (evidence level 
IIa). The same group also investigated fluvoxamine in a small study that reported a 
reduction in aggression after 12 weeks of treatment (McDougle et al., 1996) (evidence 
level IIa). In both these studies, irritability and aggression were not the primary 
outcome measures. A small study of fluoxetine reported no effect on irritability, 
although this was not the primary outcome of this (Hollander et al., 2012) (evidence 
level IIa). A small study of pregnenolone reported significant improvement in irritability  
(Fung et al., 2014) (evidence level IIb).  
 
In summary, there is limited evidence to guide the treatment of irritability in adults with 
ASD. A dopamine blocker such as risperidone or SSRI could be tried cautiously and 
side-effects should be carefully monitored (including relevant medical assessments 
and lab tests). Alternatives such as behavioural approaches should also be considered 
first (see section on non-pharmacological treatments). Further studies on 
pregnenolone are warranted. 
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10.5 Treatment of ADHD in adults with ASD 
There have not been any RCTs that have investigated the role of stimulant or non-
stimulant medications in treating ADHD in adults with ASD. In view of this we 
recommend cautiously following the BAP guidelines for treating ADHD (Bolea-
Alamañac et al., 2014), with the same general caveats discussed above for mood and 
anxiety disorders. 
 
10.6 Treatment of Tic and Tourette’s syndrome in ASD 
No current studies are available for treating tic disorders in children or adults with ASD 
specifically. A recent review (Whittington et al., 2016) on tic disorders in the absence 
of ASD reported evidence favouring the use of the a2-adrenergic receptor agonists 
clonidine and guanfacine (standardised mean difference = -0.71; 95% CI -1.03 to -
0.40; evidence level Ia). This was based on four trials with a total n = 164. As there are 
no studies on treating tic disorders in ASD we would recommend that the decision on 
using α2A receptor agonists with ASD is made on a case by case basis. 
 
10.7 Summary 
Most RCTs in ASD have centred on children and adolescents, and have 
overwhelmingly been focused on symptoms, not co-occurring disorders. There is some 
limited evidence to suggest that both treatment response and side effects to 
pharmacological interventions differ from the general population, suggesting 
extrapolation from findings in non-ASD populations should be made cautiously 
(evidence level IIb). Currently the best studied medication classes include dopamine 
blockers to target irritability and drugs targeting ADHD symptoms (methylphenidate, 
atomoxetine, α2A receptor agonists). Secondary data analyses suggest the 
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antipsychotics have modest benefits on repetitive behaviors. However, there remain 
very significant gaps in knowledge particularly with respect to some of the most 
common co-occurring conditions (e.g. anxiety and mood disorders) and some of the 
most widely prescribed drugs (e.g. antidepressants). 
 
 
Consensus recommendations of pharmacological treatment of co-occurring 
conditions and symptoms in children and adults with ASD 
 Children 
 
Adults 
Mood disorders Decision on treatment needs to 
be made on a case by case 
basis. Follow the British 
Association for 
Psychopharmacology (BAP) 
guidelines for treating 
depression 
(strength of recommendation: 
S)  
 
Decision on treatment needs to 
be made on a case by case basis. 
Follow the British Association for 
Psychopharmacology (BAP) 
guidelines for treating 
depression 
(strength of recommendation: S)  
 
Anxiety disorders Consider a cautious trial of an 
SSRIs followed by risperidone if 
poor response. Monitor for 
worsening of anxiety in some 
children.  
(strength of recommendation: 
B) 
 
Decision on treatment needs to 
be made on a case by case basis. 
Follow the British Association for 
Psychopharmacology (BAP) 
guidelines for treating anxiety 
(strength of recommendation: S)  
 
Sleep disorders Melatonin, if possible, in 
combination with a 
behavioural intervention. 
(strength of recommendation: 
A) 
 
Melatonin, if possible, in 
combination with behavioural 
intervention (extrapolation from 
findings in children) 
(strength of recommendation: S) 
 
  
60 
 
 
 
Prolonged use of 
benzodiazepines and related 
GABA agonists is not 
recommended. 
(strength of recommendation: 
S) 
 
 
Prolonged use of 
benzodiazepines and related 
GABA agonists is not 
recommended 
(strength of recommendation: S) 
 
Irritability Risperidone or aripiprazole but 
only when behavioural or 
educational approaches have 
failed. 
 
(strength of recommendation: 
A) 
 
Decision on treatment needs to 
be made on a case by case basis. 
Aripiprazole or risperidone or an 
SSRI should only be considered 
cautiously and after considering 
alternatives  
(strength of recommendation: S) 
 
ADHD First line: methylphenidate 
Second line: atomoxetine, or 
α2A receptor agonist. 
Children with ASD may 
experience more side-effects 
and show less response than 
non-ASD patients with ADHD 
(strength of recommendation: 
A) 
 
Decision on treatment needs to 
be made on a case by case basis. 
Follow the British Association for 
Psychopharmacology (BAP) 
guidelines for treating ADHD 
 
 
(strength of recommendation: S) 
Tic disorders and 
Tourette’s syndrome 
Decision on treatment needs to 
be made on a case by case 
basis 
 
(strength of recommendation: 
S) 
Decision on treatment needs to 
be made on a case by case basis 
 
(strength of recommendation: S) 
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11 Non-Pharmacological approaches for core symptoms of ASD in children. 
A full analysis of psychological interventions for ASD is beyond the scope of these 
guidelines. However, we summarise key elements of the evidence to provide context 
for the other aspects of management discussed, particularly drawing on recent NICE 
(National Institute for Health and Clinical Excellence, 2013) and the United States 
AHRQ (Weitlauf et al., 2014) reviews of behavioural interventions. 
 
11.1 Social-communication interventions 
Individual focused interventions can be delivered to young children. They are 
commonly mediated by parents, teachers or peers and can be combined with joint-
attention approaches and applied behaviour analysis (ABA). These interventions 
typically include developing patterns of communication that are directed by the child’s 
interest in activities, repeating back or expanding on what the child says, sitting close 
to the child and making eye-contact and using mirroring/imitation of the child’s actions. 
Parent-mediated interventions use parent-training programmes to improve parental 
sensitivity and responsiveness to child communication through techniques such as 
therapist-lead instruction and video feedback. Most programmes available for parents 
of children with ASD have been developed specifically for young preschool children 
with ASD. The effectiveness of such programmes has been assessed by NICE 
(National Institute for Clinical Excellence, 2012). This found there was evidence of 
efficacy for some of these programmes over treatment as usual (TAU) at reducing 
symptoms of social interaction impairment including communication acts, parent-child 
joint attention and joint engagement. However, these effects were small and often not 
clinically meaningful. For example, Green et al. (2010) compared the Preschool Autism 
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Communication Trial (PACT) to treatment as usual (TAU). ADOS-G scores were 
reduced by 3.9 points in the PACT group and 2.9 points in the TAU group, representing 
a between group effect size of -0.24. However, both parent synchrony and child 
initiations were improved in the short term by the PACT treatment (Green et al., 2010) 
and recent long-term follow-up has reported reduced ASD symptoms as measured by 
the ADOS and sustained increases in child initiations 6 years after treatment ended 
(Pickles et al., 2016). Similarly, a randomised controlled trial of Hanan’s ‘More Than 
Words’ intervention versus TAU found no main effect of treatment on child outcomes 
immediately or at five months after treatment (Carter et al., 2011). However, there were 
gains on child communication at nine-months which were moderated by baseline 
object interest (lower object interest = greater gains). Two further RCT’s of parent-
mediated interventions published after the NICE and AHRQ reviews indicate 
improvements in parent-child interactions (Kasari et al., 2014; Wetherby et al., 2014). 
 
Peer-mediated social-communication interventions can be delivered to school-aged 
children. These typically involve free-play sessions between a child with ASD and 
typically-developing children who have undergone preparatory training. There is 
evidence (level Ib) of the effectiveness of such interventions on the core feature of 
reciprocal social communication and peer-child joint engagement from four 
randomized controlled trials and one non-randomized trial (see recent review by 
Chang and Locke (2016)). However, most of these studies were conducted with high 
functioning children with ASD. Hence there is a need for further research to establish 
the effectiveness of peer-mediated interventions in other age and functional groups 
with ASD.  
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There is also evidence (level Ib) of modest gains on the quality and frequency of social 
play after the parent-assisted ‘Children’s Friendship Training (CFT)’ social skills group 
training programme (Frankel et al., 2010). This programme has also shown 
effectiveness on social skills in children with Attention-Deficit/Hyperactivity Disorder 
(Frankel et al., 1995; Frankel et al., 1997) and children with Foetal Alcohol Spectrum 
Disorders (O'connor et al., 2006). The CFT and other similar social skills interventions 
(Koenig et al., 2010; Lopata et al., 2010) typically involve mixed clinical groups with or 
without typically-developing peers and the teaching of social skills through instruction, 
modelling, rehearsal, role-play, performance feedback and homework. The CFT 
programme has been adapted for adolescents and found to have beneficial effects on 
social skills among teens 13-17 years of age (Laugeson et al., 2009).  
 
11.2 Behavioural Interventions 
Although not explicitly recommended in the NICE guidelines, the AHRQ review found 
evidence that a number of interventions based on high-intensity applied behavioural 
analysis (ABA) applied over an extended timeframe had a positive effect on cognitive 
functioning and language skills (Weitlauf et al., 2014). These interventions include the 
Learning Experiences and Alternative Program for Preschoolers and their Parents 
(LEAP), the Lovaas Model and the Early Start Denver Model (ESDM). Of the 10 studies 
included in the AHRQ review, only two were RCTs and both were conducted in the 
USA (Dawson et al., 2012; Dawson et al., 2010; Strain and Bovey, 2011), where health 
and education services may not readily generalizable to other settings. There is also 
evidence (level Ib) for combined joint attention training and ABA-based interventions. 
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Two studies reviewed by NICE (Kasari et al., 2006; Landa et al., 2011) showed large 
effects (SMD = 1.11) of additional joint-attention training for the child responding to 
joint attention during child-examiner interactions, moderate to large effects (SMD = 
0.55-0.69) on the duration of child-initiated joint attention during mother-child 
interaction and moderate effects (SMD=0.69) on pointing during examiner-child 
interaction. However, there is criticism that ABA does not generalize beyond the skills 
trained and thus should be combined with other interventions to promote the use of 
skills across settings (Smith, 2001). Hence the effectiveness of ABA may be limited to 
the specific skills taught. 
 
11.3 Alternative Interventions 
A number of alternative therapies, such as exclusion diets, secretin, chelation and 
hyperbaric oxygen therapy, have been tried for ASD. The evidence available indicates 
that exclusion diets such as gluten- or casein-free diets should not be routinely used 
for the management of core features of ASD (National Institute for Health and Clinical 
Excellence, 2013).  Moreover, the available evidence indicates that secretin treatment 
is not effective (Sandler et al., 1999). Chelation and hyperbaric oxygen therapy are 
potentially harmful with little evidence of benefit and should not be used to manage 
ASD in any context (Davis et al., 2013; National Institute for Clinical Excellence, 2012; 
Goldfarb et al., 2016). 
 
11.4 Recommendations 
We recommend considering a specific social-communication intervention for the core 
features of ASD in children and adolescents that includes play-based strategies with 
parents, carers and teachers to increase joint attention, engagement and reciprocal 
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communication. These interventions may also support the parents’, carers’, teachers’ 
or peers’ understanding of, and sensitivity and responsiveness to, the child or young 
person.  
 
Consensus recommendations of non-pharmacological approaches for children 
and adolescents 
1
.  
A specific social-communication intervention should be offered to children and 
adolescents according to their developmental level (A) 
2
. 
Social skills training should be offered to adolescents in either group or individual sessions 
(A) 
3
. 
Exclusion diets and secretin, chelation and hyperbaric oxygen therapy should not be used 
for the management of ASD in children or adolescents (D) 
 
 
12 Psychological approaches to ASD in adults 
A full analysis of psychological approaches for adults with ASD is beyond the scope of 
these BAP guidelines. In the following section, we summarize the key points to provide 
context for other aspects of management considered, drawing on the NICE guidelines 
and AHRQ review. 
 
12.1 Social Learning Programmes 
NICE guidelines recommend group- or individual social learning programmes for 
adults with ASD without a learning disability (LD) or with a mild to moderate LD, who 
have problems with social interaction. Social learning programmes to improve social 
interaction deficits apply behavioural therapy techniques within a social learning 
framework, such as using video modelling, peer/individual feedback, imitation and 
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reinforcement to teach conventions of social engagement. There is evidence (Level 
III) from observational studies in adults with ASD that suggest social skills groups may 
be effective at improving social interaction (Hillier et al., 2007; Howlin and Yates, 
1999). However, the only RCT of social skills training found no positive treatment effect 
of emotion recognition training on general emotion recognition (Golan and Baron-
Cohen, 2006), suggesting that social interaction programmes may only be effective 
when they include a more general social learning component. 
 
12.2 Behavioural and life-skills interventions 
Adults with ASD of all ranges of intellectual ability who need help with activities of daily 
living can be offered a structured, predictable training programme based on 
behavioural principles. However, the evidence (level Ib) of the effectiveness of these 
programmes is indirect and largely reliant on studies of adults with a learning disability 
(Matson et al., 1981). 
 
In adults with ASD without LD or with mild to moderate LD who are socially isolated or 
have restricted social contact, interventions should focus on the acquisition of life skills 
based on the specific need of the individual. In recent years, there has been increased 
interest in providing structured leisure activities for people with ASD. There is evidence 
(level Ib) of the effectiveness of these programmes on overall quality of life and emotion 
recognition from two RCT’s (see review by (National Institute for Clinical Excellence, 
2012)).  
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12.3 Cognitive-Behavioural Interventions 
Cognitive-behavioural therapy (CBT) can help adults with ASD across a range of 
domains. Principally, CBT is effective at treating anxiety and OCD, and supporting 
adults who have difficulties with victimisation and obtaining or maintaining 
employment. Evidence (Level I) from a systematic review demonstrates the 
effectiveness of CBT for anxiety in ASD (Lang et al., 2010). However, there is also 
evidence that anxiety management performs just as well as CBT in reducing symptoms 
of OCD in individuals with ASD (Russell et al., 2013). 
 
Cognitive-behavioural interventions can be implemented to support individuals with 
ASD who are at risk of victimisation by teaching decision-making and problem-solving 
skills. Evidence (Level Ib) from two RCTs suggests that CBT in adults with LD is 
effective at increasing skills to deal with victimisation (Khemka, 2000; Khemka et al., 
2005). However, these studies are limited by including cases without ASD. Individual 
support programmes can be used to improve employment and job retention. Studies 
of supported employment programmes are consistently positive despite 
methodological concerns including lack of randomisation in one study.  
 
12.4 Facilitated Communication 
Facilitated communication uses a facilitator to support the arm movement of an 
individual with ASD to point at letters on an alphabet board, keyboard or similar device. 
Positive reports of its effectiveness are almost exclusively based on anecdotal 
evidence (Biklen, 1990; Biklen et al., 1992; Biklen et al., 1995; Biklen and Schubert, 
1991; Clarkson, 1994; Crossley and Remington-Gurney, 1992; Heckler, 1994; Janzen-
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Wilde et al., 1995; Olney, 1995; Sabin and Donnellan, 1993; Sheehan and Matuozzi, 
1996; Weiss et al., 1996). There is no evidence of positive effects from any scientific 
study(Bebko et al., 1996; Beck and Pirovano, 1996; Bomba et al., 1996; Braman et al., 
1995; Crews et al., 1995; Eberlin et al., 1993; Edelson et al., 1998; Hirshoren and 
Gregory, 1995; Hudson et al., 1993; Klewe, 1993; Konstantareas and Gravelle, 1998; 
Montee et al., 1995; Myles and Simpson, 1994; Myles et al., 1996; Oswald, 1994; 
Regal et al., 1994; Simon et al., 1996; Simpson and Myles, 1995a; Smith and Belcher, 
1993; Smith et al., 1994; Szempruch and Jacobson, 1993; Vázquez, 1994; Wheeler et 
al., 1993). In addition to the lack of empirical support, there is evidence that facilitated 
communication can lead to significant harm. For example, there have been 
unsubstantiated claims of sexual abuse against family members made when using 
facilitated communication (Rimland, 1992; Simpson and Myles, 1995b). For these 
reasons, the National Institute for Health and Clinical Excellence strongly recommends 
that facilitated communication is not used (National Institute for Clinical Excellence, 
2012). 
 
 
12.5 Recommendations 
It is recommended that adults with ASD are offered psychological interventions to 
optimise personal functioning, including developing the skills necessary for access to 
public transport, employment and leisure facilities. Interventions should focus on 
supporting access to community activities and increasing the individual’s quality of life. 
Furthermore, psychological approaches can be used to help with acceptance of their 
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difficulties, treat co-occurring conditions and to teach life skills specific to the needs of 
the individual.  
 
Consensus recommendations of psychological approaches with adults 
1
.  
For adults with problems with social interaction, consider a group or individual social-
learning programme (A). 
2
. 
Do not provide facilitated communication for adults with ASD (D) 
3
. 
For adults who need help with activities of daily living, consider offering training 
programmes based on behavioural principles (A) 
 
 
13 Service Provision 
The NICE guidelines published in 2011 recommend the development of multi-agency 
teams for people with ASD that include representatives from child health and mental 
health services, education, social care and the voluntary sector. However, service 
provision varies greatly and in many settings is significantly weighted towards 
diagnosis and children’s services rather than treatment and support or adult care. In 
particular, there are unmet needs around common co-existing conditions including 
feeding problems, sleep problems, anxiety, hyperactivity and sensory problems 
(Maskey et al., 2013). Unfortunately, there has been very little health service research 
that has focused on ASD. In view of this, we review the available evidence below and 
make recommendations for service provision for children and adults, but it should be 
appreciated that these are largely based on the expert opinion of the working group.  
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13.1 Diagnostic services 
Timely and valid diagnosis is important as early diagnosis and provision of appropriate 
management services is likely to improve long-term outcome (Magiati et al., 2014; 
Oono et al., 2013). Referral and diagnostic pathways for ASD vary, but in most cases, 
the initial concerns raised by parents or professionals will be directed to a general 
practitioner (GP), speech and language therapist or an educational psychologist. 
These will undertake an initial assessment and decide to refer the patient to children’s 
health or mental health services for a full assessment. A full assessment should be 
made by professionals who are trained in the assessment, diagnosis and treatment of 
ASD using a combination of diagnostic tools, assessments and clinical experience 
(level IV). In general, diagnosis should not be formulated by one single professional 
and should involve a multi-disciplinary team (MDT) (Penner et al., 2017). This should 
ideally consist of a speech and language therapist, a clinical psychologist, 
paediatrician or child psychiatrist and an occupational therapist. However, there is 
significant variation in service provision. For example, 47% of teams surveyed in the 
UK do not have access to a clinical psychologist (Palmer et al., 2010).  
 
 It is noteworthy that studies from some settings report a correlation between lower 
socioeconomic status and later diagnosis (Goin-Kochel et al., 2006), suggesting that 
there are social impediments to referral and diagnosis. However, studies in settings 
where there is universal free health care (such as the UK) do not show this relationship, 
or even show the opposite relationship (Brett et al., 2016). Other factors reportedly 
associated with earlier age of diagnosis in the UK include a ‘core’ ASD diagnosis (as 
opposed to broader ASD), language regression or delay, and greater degree of 
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support needed (Brett et al., 2016). Furthermore, there is evidence of a sex bias in 
referral and diagnosis even in settings such as the UK, suggesting a delayed 
recognition of the disorder in young girls (Rutherford et al., 2016; Brett et al., 2016). 
Moreover, within the UK there is regional variation in the diagnostic services available 
(Parr et al., 2013; Gray et al., 2015; Palmer et al., 2010) (level IV). 
 
Given these findings, there is a need for clear referral pathways that ensure adequate 
assessment is available to all who need it (Buckley, 2016). This needs to be coupled 
with increased training to raise awareness of ASD among GP’s and healthcare visitors 
(level IV).  
 
13.2 Management/Treatment services 
Given the complexity of ASD, its treatment and monitoring should be conducted by 
professionals who are trained and experienced in treating and monitoring ASD (S). For 
patients with severe symptoms, a structured multi-disciplinary approach that includes 
regular reviews of the overall care package, such as the care programme approach, is 
indicated (S). Ideally, treatment should be managed by a specialist MDT with 
experience in ASD and related disorders. Where this is not possible, services should 
consider a consultation-liaison model where recommendations are made by a 
specialist team but implemented by general health services such as general 
psychiatrists, paediatricians or GP’s, with further liaison depending on response (S).  
 
Individuals with ASD who are in child and adolescent services should be reassessed 
around 14 years of age to establish the need for continuing treatment into adulthood 
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(S) (National Institute for Health and Clinical Excellence, 2013). Where on-going 
treatment is required, arrangements should be made for a smooth transition into adult 
services and the individual kept informed about the treatment and services available 
to them (S) (National Institute for Health and Clinical Excellence, 2013). Information 
about adult services should be provided to the young person, and their parents or 
carers, including their right to a social care assessment at age 18 (S). 
 
Finally, there is a clear need for health services research to evaluate diagnostic and 
treatment service models, both in terms of clinical outcomes and cost-effectiveness. 
 
13.3 Improving services 
Given the importance of timely diagnosis, early identification and referral is a priority. 
GP initiatives and specialist training for health visitors is recommended to improve 
early identification (S). Diagnostic and treatment services should be led by multi-
disciplinary teams that consist of a minimum of a psychiatrist (or paediatrician where 
appropriate) and a speech and language therapist and a psychologist. Treatment 
recommendations should be made alongside diagnosis and followed up by a team 
experienced in treating ASD, using a structured care approach, such as the Care 
Programme Approach, particularly for people with severe and complex needs.  There 
is a possibility that referral rates for ASD will increase given the greater public 
awareness and diagnostic service availability. This poses a challenge to services that 
are trying to provide a valid and timely diagnosis. It is therefore important to use 
screening tools in order to target service resources. Finally, it is important to consider 
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costs when assessing current services or developing new ones. Services should be 
audited regularly to ensure quality and accessibility of care for patients. 
 
13.4 Recommendations 
 
There is large variation in services between settings and little research on the optimum 
service provision or cost-effectiveness. There is a need for well-designed studies to 
evaluate models of service provision, and randomized controlled studies developed to 
test these using patient experience, functional outcomes in addition to standard clinical 
measures (strength of recommendation: D). Finally, it is important to consider costs 
when assessing current services or developing new ones, and future studies of service 
provision should include cost-analysis (strength of recommendation: D). Services 
should be audited regularly to ensure quality and accessibility of care for patients 
(strength of recommendation: D). 
 
Consensus recommendations for service provision 
1
.  
Reassess individuals with ASD in children’s services during adolescence well in advance 
of the transition date to establish the need for continuing treatment (S). 
2
. 
If continuing treatment is necessary, make arrangements for a smooth transition to adult 
services or GP and give information to the young person about the treatment and services 
they may need (S). 
3
. 
For young people and adults whose needs are complex or severe, use the care 
programme approach or similar structured approach to coordinate their needs and to aid 
the transfer between services (S). 
4
. 
Involve the individual with ASD in care planning and, where appropriate, their parents or 
carers (S). 
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5
. 
Provide information about adult services to the young person, and their parents or carers, 
including their right to a social care assessment at age 18 (S). 
 
 
14 Future directions 
The earlier sections have highlighted that there are a number of limitations and areas 
of uncertainty, particularly for core ASD symptoms. The following section discusses 
these and makes recommendations for future research. 
14.1 Future design of clinical trials 
Many studies are open-label and/or small scale, or lack an adequate placebo group. 
Hence, there is a general need for positive findings from these initial exploratory and 
proof-of-concept studies to be followed-up with large-scale randomized placebo-
controlled trials. This presents a number of challenges for the field. First, as some 
potentially useful treatments are off-patent, the field will not be able to rely on the 
pharmaceutical industry to fund studies of these compounds. Thus, funding will need 
to be sought from other sources, including government funded agencies and charities 
and foundations. Second, the field will need infrastructure for large-scale trials across 
many settings. This will also involve centres developing the capacity to screen and 
recruit people with ASD to clinical trials, and is likely to benefit from the involvement of 
support groups and charities (Warnell et al., 2015) (strength of recommendation: D). 
  
One major limitation of the literature to date is that only a small number of clinical trials 
have included participants below the age of five. Interventions that begin before the 
age of five may have the most dramatic effect (Aman et al., 2015) as ASD symptoms 
start emerging and brain plasticity is at its peak during this period. However, there are 
  
75 
 
 
important safety considerations regarding the use of pharmacological interventions in 
paediatric populations (Kearns et al., 2003). Consequently, it will be necessary to 
develop and trial interventions in this period both to prevent the onset of ASD and 
minimize its effects on brain and cognitive development (strength of recommendation: 
D). Another general limitation of studies to date is that individuals with ASD who have 
an intellectual disability are usually excluded, despite the fact that over a third of people 
with ASD have an intellectual disability (Baio, 2012). Thus, to be representative, future 
studies should include people with ASD and intellectual disability, and need to adopt 
designs that facilitate this (strength of recommendation: D). Clearly both these issues 
will involve overcoming the ethical and practical challenges of enrolling young children 
and people with intellectual disability into clinical trials. This may be helped by wider 
engagement with individuals and their families regarding the design of clinical trials. 
Another issue that needs addressing is the duration of trials, which have mostly been 
weeks or at most a few months to date. Given the long-standing and pervasive nature 
of core symptoms, it is highly unlikely that core symptoms will improve in a few weeks 
or months and, where there is change, it is necessary to show that this is sustained 
(strength of recommendation: D).  
14.2 Non-Pharmacological interventions and service provision 
 
There is a lack of large-scale, multicentre RCT’s investigating the effectiveness of 
social-communication interventions, applied behavioural analysis (ABA), 
behaviourally-based life skills training and anti-victimisation CBT. Studies are required 
to assess the effectiveness of these interventions across a range of outcome 
measures including cost-effectiveness and quality of life (strength of recommendation: 
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D). Similarly, models of service provision are under-tested and require empirical 
evaluation (strength of recommendation: D). These studies should use patient 
experience and functional outcomes in addition to standard clinical measures of 
improvement.  
 
14.3 Future outcome measures 
Another critical issue that needs to be addressed is the lack of agreement on the 
outcome measures to be used in trials to accurately capture changes in core ASD 
symptoms over time (Aman et al., 2004). An optimal tool needs to be reliable and 
suitable for repeated administration. Current functioning should also be a focus. Aman 
and colleagues provide a comprehensive review of potential instruments and also point 
out that other aspects such as language, intellectual level and adaptive behaviour 
should be incorporated in the outcome measures (Aman et al., 2004) (strength of 
recommendation: D). Another obstacle that needs to be considered in pharmacological 
studies is that in the absence of objective psychometric measures, evaluation of 
symptom change in children depends on the parent- report measures, which are prone 
to expectancy bias (Aman et al., 2015). Thus, blinding and placebo control is important, 
and findings from open-label studies should be treated with caution. Last, but not least, 
the perspective of individuals with ASD and their carers should be taken into account 
when deciding on outcome measures. A recent systematic review highlighted the 
disparity in the outcomes identified as important by parents and those identified by 
health professionals: parents highlighted the importance of social participation and 
emotional well–being, whereas health professionals concentrated on the content of the 
available instruments they have (McConachie et al., 2015). A tool that indexes the 
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quality of life of individuals with ASD that should be included as an outcome measure 
in future clinical trials (strength of recommendation: D). Furthermore, monitoring of 
adverse effects should not be limited to studies of pharmacological interventions. 
Adverse effects should be monitored when studying psychological and other 
interventions too.  
 
14.4 The challenge of biological heterogeneity 
On top of these difficulties in designing clinical trials, another challenge is the genetic 
and neurobiological heterogeneity seen in ASD, which means that it is unlikely that 
any single drug will be effective for all patients. It is clear we need better understanding 
of the neurobiology underlying ASD to identify key molecular and system pathways 
that are disrupted, and the determinants of heterogeneity. This will enable the 
development of treatments that target key components of the neurobiology. Coupled 
with this we need biomarkers to identify sub-types that will respond to particular 
approaches (Loth et al., 2016b). A considerable amount of work is currently on-going 
to develop imaging, genetic, proteomic and other biomarkers for this purpose (eg: 
https://www.ncbi.nlm.nih.gov/pubmed/28649312). To date there is no independently 
validated biomarker for stratification of patients and trials have rarely attempted to 
include biomarkers that would enable stratification. Thus, it is largely unknown if there 
are sub-groups that showed better or worse response in past trials.  
 
Syndromic types of ASD with a defined genetic basis can be used in the absence of 
biomarkers. Pathophysiological changes are likely to more homogenous in syndromic 
ASD (e.g. fragile X syndrome; FXS). As discussed earlier, open label studies on FXS 
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using lithium (Berry-Kravis et al., 2008) and minocycline (Paribello et al., 2010) have 
shown encouraging results, suggesting the potential of this approach, although studies 
need to be replicated in randomized, double blind controlled studies. This highlights 
two over-riding issues; first of all, the level of complexity in the neurobiology of ASD 
(Ghosh et al., 2013) and secondly the importance of either conducting the studies in a 
clinically and biologically homogenous groups or including biomarkers to stratify 
heterogenous groups. 
 
So far, the identification of putative subgroups has been limited by small sample sizes, 
which limits the power of studies to test the influence of stratification by sub-groups on 
treatment response. Small discovery studies need to be followed by larger studies with 
the power to test the clinical utility of the potential biomarkers they identify (strength of 
recommendation: D). Therefore, in the future, large-scale, multicenter studies where 
patients are stratified according to their biological subtype are necessary in order to 
test whether stratification by particular biomarkers corresponds to improved response 
in a sub-group (strength of recommendation: D). In these studies, subgroups may be 
identified according to their genetic or molecular profile and then subsequently 
compared in terms of cognitive, neuroimaging and biochemical measures (Loth et al., 
2016a). These advances will hopefully make it possible to identify biomarkers which, 
in the future, can be used to treat individuals with ASD more effectively and with a 
more personalized approach.   
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Consensus recommendations for future research directions 
Studies should include biomarkers to identify potential sub-groups in order to support 
stratification in future clinical trials where possible. (D) 
 
Clinical trials should ideally be multicentre, large-scale and include biomarkers where 
possible. This will ensure results are more generalizable and offer the opportunity to test 
whether a change in outcome measures is associated with change in biomarkers. (D) 
 
Clinical trials should include younger children and individuals with ASD and intellectual 
disability to ensure generalizability to the whole population of people with ASD. (D) 
 
Longer-term clinical trials lasting at least 6 months are required. (D) 
 
There is a need to develop objective outcome measures that can reliably capture changes 
of core symptoms over time. (D) 
 
Clinical trials should also include measures of quality of life of individuals with ASD. (D) 
 
Large-scale, multicentre, RCT’s are needed to assess the effectiveness of social-
communication interventions and applied behavioural analysis on a range of outcome 
measures. (D) 
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All interventional studies, including those investigating psychological and social 
interventions, should include measures of adverse effects (D)  
Studies are needed to examine the effectiveness of behaviourally based daily life skills in 
adults with ASD. (D) 
Studies are needed to examine the effectiveness of anti-victimisation CBT in adults with 
ASD (D) 
Studies are needed to evaluate models of service provision using patient experience and 
functional outcomes in addition to standard clinical measures (D). 
 
 
 
 
15 Summary of guidelines and conclusions 
These guidelines present recommendations based on the current literature and expert 
opinion for the diagnosis and management of ASD in children and adults. Our review 
of the evidence is not intended to be exhaustive, but to highlight key findings and also 
place them in a clinical context, drawing from the practical experience of the 
contributors. We hope that this balance will help the clinician who draws on the 
guidelines to place the evidence and our recommendations in the individual context of 
the person with ASD in front of them. 
  
Current evidence does not support the routine use of any pharmacological treatment 
for the core symptoms of ASD. The evidence base is growing, particularly for co-
occurring symptoms and disorders, yet much of the evidence is relatively nascent, 
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particularly for core aspects of ASD. Aripiprazole and risperidone have shown some 
benefit for repetitive behaviours but are recommended only on a case-by-case basis 
in view of the risk of side-effects. There are a number of treatments for co-occurring 
conditions with a reasonable evidence base, although the evidence is still largely 
limited to symptomatology and mainly limited to children. In children, melatonin is 
recommended for sleep disorders, risperidone and aripiprazole may be cautiously 
used in the management of irritability if behavioural approaches are not possible, and 
methylphenidate is recommended for ADHD symptoms. There is very limited evidence 
for treatments for other co-occurring symptoms or disorders and in adults. 
Consequently, treatment is guided by extrapolation from studies in people without 
ASD. As treatment response and side-effect profiles in ASD may differ from the general 
population, treatment guided by extrapolation from studies in people without ASD must 
be cautious. Therefore, each treatment for an individual with ASD should be 
approached as an n = 1 trial with careful evaluation of both benefits and side-effects. 
 
In children and adolescents, social-communication interventions should be offered to 
increase joint-attention, engagement and reciprocal communication. In adults, 
psychological interventions should focus on the acquisition of life skills, access to 
community activities and quality of life. 
 
ASD is a common and pervasive condition with a high health burden, and complex 
pathoaetiology involving a number of brain systems. The impact of ASD on the 
individual, their family and wider society is substantial, but may be reduced by timely 
diagnosis, the use of effective treatments, and avoiding inappropriate treatment. We 
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recommend that service providers ensure people with ASD have timely access to 
diagnostic and treatment services with specialist expertise in ASD. Research into the 
genetics and neurobiology of ASD indicates that there is significant genetic and 
neurobiological heterogeneity. This is likely to lead to heterogeneity in response to 
treatment and differential sensitivity to side-effects. It also highlights the need for 
biomarkers that can be used to guide the development of new treatments for core 
symptoms and co-occurring conditions, and help identify sub-groups who may respond 
better. Our analysis of the current evidence also highlights particular key gaps and 
limitations, and makes recommendations to address these. There are a number of 
studies of promising treatments being developed and we hope our recommendations 
will inform the development of studies. Finally, it is important to appreciate that we do 
not see these guidelines as set in stone. Indeed, we look forward to the evidence base 
growing, and anticipate revising these guidelines in the light of future developments. 
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